<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1808210954
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Laroza
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LURASIDONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        80
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        196.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jazeera Pharmaceutical Industries (JPI)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AE05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Laroza is a prescription medicine used:</p><p style="text-align:justify">&middot;&nbsp;&nbsp;To treat people 13 years of age or older with schizophrenia</p><p style="text-align:justify">&middot;&nbsp;&nbsp;Alone to treat people 10 years of age and older with depressive episodes that happen with Bipolar l Disorder (bipolar depression).</p><p style="text-align:justify">&middot;&nbsp;&nbsp;With the medicine lithium or valproate to treat adults with depressive episodes that happen with Bipolar l Disorder (bipolar depression).</p><p style="text-align:justify">It is not known if lurasidone is safe and effective in children:</p><p style="text-align:justify">&middot;&nbsp;&nbsp;Less than 13 years of age with schizophrenia</p><p style="text-align:justify">&middot;&nbsp; Less than 10 years of age with bipolar depression</p><p style="text-align:justify">For the treatment of irritability associated with autistic disorder.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify"><strong>Do not take Laroza</strong></p><p style="text-align:justify">&middot;&nbsp;&nbsp;Allergic to lurasidone hydrochloride or any of the ingredients in Laroza. See the end of this package leaflet for a complete list of ingredients in Laroza.</p><p style="text-align:justify">&middot; Taking certain other medicines called CYP3A4 inhibitors or inducers including ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, rifampin, avasimibe, St. John&rsquo;s wort, phenytoin, or carbamazepine. Ask your healthcare provider if you are not sure if you are taking any of these medicines.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Warnings and Precautions </strong></p><p style="text-align:justify">Before taking Laroza, tell your healthcare provider about all of your medical conditions, including if you:</p><p style="text-align:justify">&middot;&nbsp;&nbsp;Have or have had heart problems or stroke</p><p style="text-align:justify">&middot;&nbsp;&nbsp;Have or have had low or high blood pressure</p><p style="text-align:justify">&middot;&nbsp;&nbsp;Have or have had diabetes or high blood sugar or have a family history of diabetes or high blood sugar.</p><p style="text-align:justify">&middot;&nbsp;&nbsp;Have or have had high levels of total cholesterol or triglycerides</p><p style="text-align:justify">&middot;&nbsp;&nbsp;Have or have had high prolactin levels</p><p style="text-align:justify">&middot;&nbsp;&nbsp;Have or have had low white blood cell count</p><p style="text-align:justify">&middot;&nbsp;&nbsp;Have or have had seizures</p><p style="text-align:justify">&middot;&nbsp;&nbsp;Have or have had kidney or liver problems</p><p style="text-align:justify">&middot;&nbsp;&nbsp;Are pregnant or plan to become pregnant. It is not known if lurasidone will harm your unborn baby. Talk to your healthcare provider about the risk to your unborn baby if you take lurasidone during pregnancy.</p><p style="text-align:justify">-&nbsp;&nbsp;Tell your healthcare provider if you become pregnant or think you are pregnant during treatment with Laroza</p><p style="text-align:justify">&middot;&nbsp;Are breastfeeding or plan to breastfeed. It is not known if lurasidone passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during the treatment with lurasidone.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Other medicines and </strong><strong>Laroza</strong></p><p style="text-align:justify">Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p><p style="text-align:justify">Laroza and other medicines may affect each other causing possible serious side effects. Laroza may affect the way other medicines work, and other medicines may affect how Laroza works.</p><p style="text-align:justify">Your healthcare provider can tell you if it is safe to take Laroza with your other medicines. Do not start or stop any other medicines during treatment with Laroza without talking to your healthcare provider first.</p><p style="text-align:justify">Know the medicines you take. Keep a list of your medicines to show your healthcare provider and pharmacist when you get a new medicine.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Laroza</strong> <strong>with food, drink and alcohol</strong></p><p style="text-align:justify">Avoid eating grapefruit or drinking grapefruit juice during treatment with Laroza. Grapefruit and grapefruit juice may affect the amount of Laroza in your blood.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Driving and using machines</strong></p><p style="text-align:justify">Do not drive, operate heavy machinery, or do other dangerous activities until you know how Laroza affects you. Laroza may make you drowsy.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Pregnancy and breast-feeding</strong></p><p style="text-align:justify">Before taking Laroza, tell your healthcare provider if you:</p><p style="text-align:justify">&middot;&nbsp;&nbsp;Are pregnant or plan to become pregnant. It is not known if lurasidone will harm your unborn baby. Talk to your healthcare provider about the risk to your unborn baby if you take lurasidone during pregnancy.</p><p style="text-align:justify">-&nbsp;Tell your healthcare provider if you become pregnant or think you are pregnant during treatment with Laroza</p><p style="text-align:justify">&middot;&nbsp;&nbsp;Are breastfeeding or plan to breastfeed. It is not known if lurasidone passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with lurasidone.</p><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify"><strong>Laroza contains lactose monohydrate.</strong></p><p style="text-align:justify">Laroza contains lactose monohydrate.</p><p style="text-align:justify">Each 20 mg film-coated tablet contains 31.80 mg lactose monohydrate.</p><p style="text-align:justify">Each 40 mg film-coated tablet contains 63.60 mg lactose monohydrate.</p><p style="text-align:justify">Each 80 mg film-coated tablet contains 127.20 mg lactose monohydrate.</p><p style="text-align:justify">Each 120 mg film-coated tablet contains 190.80 mg lactose monohydrate.</p><p style="text-align:justify">If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; Take Laroza exactly as your healthcare provider tells you to take it. Do not change the dose or stop taking Laroza without first talking to your healthcare provider.</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; Take Laroza by mouth, with food (at least 350 calories).</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; If you take too much Laroza, call your healthcare provider or poison control center or go to the nearest hospital emergency room right away.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>What should I avoid while taking Laroza</strong></p><p style="text-align:justify">&middot;&nbsp;&nbsp;Do not drive, operate heavy machinery, or do other dangerous activities until you know how Laroza affects you. Laroza may make you drowsy</p><p style="text-align:justify">&middot;&nbsp;&nbsp;Avoid eating grapefruit or drinking grapefruit juice during treatment with Laroza. Grapefruit and grapefruit juice may affect the amount of Laroza in your blood.</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; Do not become too hot or dehydrated during treatment with Laroza</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Do not exercise too much.</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; In hot weather, stay inside in a cool place if possible.</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Stay out of the sun.</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Do not wear too much clothing or heavy clothing.</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Drink plenty of water.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify"><strong>Lurasidone</strong> <strong>may cause serious side effects, including: </strong></p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; Stroke (cerebrovascular problems) in elderly people with dementia-related psychosis that can lead to death.</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; Neuroleptic malignant syndrome (NMS) a serious condition that can lead to death. Call your healthcare provider or go to the nearest hospital emergency room right away if you have some or all of the following signs and symptoms of NMS:</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; High fever&nbsp;</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Stiff muscles&nbsp;</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Confusion</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Increased sweating</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Changes in your breathing, heart rate, and blood pressure</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; Uncontrolled body movements (tardive dyskinesia). Laroza may cause movements that you cannot control in your face, tongue, or other body parts. Tardive dyskinesia may not go away, even if you stop taking Laroza. &nbsp;Tardive dyskinesia may also start after you stop taking Laroza.</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; Problems with your metabolism such as:</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; High blood sugar (hyperglycemia) and diabetes.<strong> </strong>Increase in blood sugar can happen in some people who take Laroza. Extremely high blood sugar can lead to coma or death. If you have diabetes or risk factors for diabetes (such as being overweight or a family history of diabetes), your healthcare provider should check your blood sugar before you start and during treatment with Laroza</p><p style="text-align:justify">Call your healthcare provider if you have any of these symptoms of high blood sugar during treatment with Laroza:</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Feel very thirsty</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Need to urinate more than usual&nbsp;</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Feel very hungry</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Feel weak or tired</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Feel sick to your stomach</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Feel confused, or your breath smells fruity</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Increased fat levels (cholesterol and triglycerides) in your blood.</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Weight gain. You and your healthcare provider should check your weight regularly during treatment with Laroza.</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; Increased prolactin levels in your blood (hyperprolactinemia). Your healthcare provider may do blood tests to check your prolactin levels during treatment with Laroza. Tell your healthcare provider if you have any of the following signs of hyperprolactinemia:</p><p style="text-align:justify"><em>Females:</em></p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Absence of your menstrual cycle</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Secretion of breast milk when you are not breastfeeding</p><p style="text-align:justify"><em>Males:</em></p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Problems getting or maintaining an erection (erectile dysfunction)</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Enlargement of breasts (gynecomastia)</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; Low white blood cell count. Your healthcare provider may do blood tests during the first few months of treatment with Laroza</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; Decreased blood pressure (orthostatic hypotension). You may feel lightheaded or faint when you rise too quickly from a sitting or lying position.</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; Falls. Laroza may make you sleepy or dizzy, may cause a decrease in your blood pressure when changing position (orthostatic hypotension) and can slow your thinking and motor skills which may lead to falls that can cause fractures or other injuries.</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; Seizures (convulsions)</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; Problems controlling your body temperature so that you feel too warm. See &ldquo;What should I avoid while taking Laroza&rdquo;.</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; Mania or hypomania (manic episodes) in people with a history of bipolar disorder. Symptoms may include:</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Greatly increased energy</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Severe problems sleeping</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Racing thoughts</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Reckless behavior</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Unusually grand ideas</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Excessive happiness or irritability</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Talking more or faster than usual</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; Difficulty swallowing</p><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify"><strong>The most common side effects of lurasidone in adults include: </strong></p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; Adults with schizophrenia:</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Sleepiness or drowsiness</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Restlessness and feeling like you need to move around (akathisia)</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Difficulty moving, slow movements, muscle stiffness, or tremor</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Nausea</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; Children 13 to 17 years of age with schizophrenia</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Sleepiness or drowsiness</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Nausea</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Restlessness and feeling like you need to move around (akathisia)</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Difficulty moving, slow movements, muscle stiffness, or tremor</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Runny nose</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Vomiting</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; Adults with bipolar depression</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Restlessness and feeling like you need to move around (akathisia)</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Difficulty moving, slow movements, muscle stiffness, or tremor</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Sleepiness or drowsiness</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; Children 10 to 17 years of age with bipolar depression</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Nausea</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Weight gain</p><p style="text-align:justify">-&nbsp;&nbsp;&nbsp; Problems sleeping (insomnia)&nbsp;</p><p style="text-align:justify">These are not all of the possible side effects of lurasidone.</p><p style="text-align:justify">Call your doctor for medical advice about side effects.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Keep this medicine out of the sight and reach of children.</p><p style="text-align:justify">Do not store above 30&deg;C.</p><p style="text-align:justify">Store in the original package.</p><p style="text-align:justify">Do not use this medicine after the expiry date which is stated on the carton after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p style="text-align:justify">Do not use this medicine if you notice any visible signs of deterioration.</p><p style="text-align:justify">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">The active substance is lurasidone hydrochloride.</p><p style="text-align:justify">Each film-coated tablet of Laroza 20 mg Film-coated Tablet contains 20 mg lurasidone hydrochloride.</p><p style="text-align:justify">Each film-coated tablet of Laroza 40 mg Film-coated Tablet contains 40 mg lurasidone hydrochloride.</p><p style="text-align:justify">Each film-coated tablet of Laroza 80 mg Film-coated Tablet contains 80 mg lurasidone hydrochloride.</p><p style="text-align:justify">Each film-coated tablet of Laroza 120 mg Film-coated Tablet contains 120 mg lurasidone hydrochloride.</p><p style="text-align:justify">The other ingredients are lactose monohydrate, mannitol, pregelatinized starch, croscarmellose sodium, povidone, citric acid anhydrous, magnesium stearate and Opadry white 03B28796 (Hypromellose, titanium dioxide and polyethylene glycol).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Laroza 20 mg Film-coated Tablets are white to off-white round shaped tablets, embossed with L1 on one side and plain on other side in aluminum-aluminum blisters.

Laroza 40 mg Film-coated Tablets are white to off-white round shaped tablets, embossed with L2 on one side and plain on other side in aluminum-aluminum blisters.

Laroza 80 mg Film-coated Tablets are white to off white oval shaped tablets, embossed with L3 on one side and plain on other side in aluminum-aluminum blisters.

Laroza 120 mg Film-coated Tablets are white to off white oval shaped tablets, embossed with L4 on one side and plain on other side in aluminum-aluminum blisters.

Pack size: 30 Film-coated Tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 4980170&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br />Fax: + (966-11) 4980187<br />e-mail: medical@jpi.com.sa</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 4980170&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br />Fax: + (966-11) 4980187<br />e-mail: medical@jpi.com.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 05/2019; version number SA1.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL" style="text-align:justify">لاروزا هو دواء يصرف بوصفة طبية ويستخدم:</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;في علاج الأشخاص البالغة أعمارهم 13 عاماً أو فما فوق ممن يعانون من انفصام الشخصية</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;بمفرده في علاج الأشخاص البالغة أعمارهم 10 أعوام فما فوق ممن يعانون من نوبات اكتئاب مصاحبة لاضطراب ثنائي القطب من النوع الأول (الاكتئاب ثنائي القطب).</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;مع دواء الليثيوم أو الفالبروات لعلاج البالغين المصابين بنوبات اكتئاب مصاحبة لاضطراب ثنائي القطب من النوع الأول (الاكتئاب ثنائي القطب).</p><p dir="RTL" style="text-align:justify">ليس معروفاً إذا ما كان لوراسيدون آمناً وفعّالاً لدى الأطفال:</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;الأقل من 13 عاماً المصابين بانفصام الشخصية</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;الأقل من 10 أعوام المصابين باكتئاب ثنائي القطب</p><p style="text-align:justify">لعلاج التهيّج المرتبط باضطراب التوحّد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify"><strong>لا تستخدم لاروزا</strong><strong> </strong><strong>إذا كنت:</strong></p><p dir="RTL" style="text-align:justify">&middot;&nbsp;تعاني من حساسية لهيدروكلوريد اللوراسيدون أو لأي من المواد الأخرى المستخدمة في تركيبة لاروزا. انظر نهاية نشرة هذه العبوة لمعرفة قائمة مكونات لازورا الكاملة.</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;تتناول أدوية محددة أخرى تسمى محفزات أو مثبّطات CYP3A4 تشتمل: كيتوكونازول، كلاريثروميسين، ريتونافير، فوريكونازول، ميبيفراديل، ريفامبين، أفاسيميب، نبتة سانت جون، فينيتوين، أو كاربامازيبين. اسأل مقدم الرعاية الصحية إذا لم تكن متأكداً في حال ما كنت تتناول أيّاً من هذه الأدوية.</p><p dir="RTL" style="text-align:justify">&nbsp;</p><p dir="RTL" style="text-align:justify"><strong>الاحتياطات والتحذيرات </strong></p><p dir="RTL" style="text-align:justify">قبل تناول لاروزا، أخبر مقدم الرعاية الصحية عن جميع الحالات الطبية التي تعاني منها، بما في ذلك إذا:</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; كنت تعاني أو عانيت في السابق من مشاكل في القلب أو السكتة الدماغية</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; كنت تعاني أو عانيت في السابق من ارتفاع ضغط الدم أو انخفاضه</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; كنت تعاني أو عانيت في السابق من مرض السكري أو ارتفاع السكر في الدم أو كان يوجد لديك تاريخ عائلي من مرض السكري أو ارتفاع السكر في الدم.</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; كنت تعاني أو عانيت في السابق من ارتفاع مستويات الكوليسترول الإجمالي أو الدهون الثلاثية</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; كنت تعاني أو عانيت في السابق من ارتفاع مستويات البرولاكتين</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; كنت تعاني أو عانيت في السابق من انخفاض عدد خلايا الدم البيضاء</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; كنت تعاني أو عانيت في السابق من نوبات الصرع</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; كنت تعاني أو عانيت في السابق من مشاكل في الكلى أو الكبد</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; كنتِ حاملاً أو تخططين لحدوث حمل. من غير المعروف ما إذا كان لوراسيدون سيضر بجنينك. تحدثي مع مقدم الرعاية الصحية حول المخاطر التي يتعرض لها جنينك إذا كنتِ تتناولين لوراسيدون خلال فترة الحمل.</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; أخبري مقدم الرعاية الصحية في حال حدوث حمل أو إذا كنتِ تعتقدين بأنك حاملاً أثناء العلاج بلاروزا</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; كنتِ تقومين بالرضاعة الطبيعية أو تخططين للرضاعة الطبيعية. من غير المعروف ما إذا كان لوراسيدون ينتقل إلى حليب الثدي. تحدثي مع مقدم الرعاية الصحية عن أفضل طريقة لتغذية طفلك أثناء العلاج بلوراسيدون.</p><p dir="RTL" style="text-align:justify">&nbsp;</p><p dir="RTL" style="text-align:justify"><strong>الأدوية الأخرى </strong><strong>ولاروزا</strong></p><p dir="RTL" style="text-align:justify">أخبر مقدم الرعاية الصحية عن جميع الأدوية التي تتناولها بما في ذلك الأدوية التي يتم صرفها بوصفة طبية وبدون وصفة طبية، الفيتامينات والمكملات العشبية.</p><p dir="RTL" style="text-align:justify">قد يؤثر لاروزا والأدوية الأخرى على بعضهما، مما يسبب آثاراً جانبية خطيرة محتملة. قد يؤثر لاروزا على طريقة عمل الأدوية الأخرى، وقد تؤثر الأدوية الأخرى على طريقة عمل لاروزا.</p><p dir="RTL" style="text-align:justify">يمكن أن يخبرك مقدم الرعاية الصحية إذا ما كان تناول لاروزا مع أدويتك الأخرى آمناً. لا تبدأ أو تتوقف عن تناول أي أدوية أخرى أثناء العلاج بلاروزا دون التحدث مع مقدم الرعاية الصحية أولاً.</p><p dir="RTL" style="text-align:justify">كن على معرفة بالأدوية التي تتناولها. احتفظ بقائمة بأدويتك لعرضها على مقدم الرعاية الصحية والصيدلي عند حصولك على دواء جديد.</p><p dir="RTL" style="text-align:justify">&nbsp;</p><p dir="RTL" style="text-align:justify"><strong>لاروزا</strong> <strong>مع الطعام، الشراب والكحول</strong></p><p dir="RTL" style="text-align:justify">تجنب تناول الجريب فروت أو شرب عصير الجريب فروت أثناء العلاج بلاروزا. قد يؤثر الجريب فروت وعصير الجريب فروت على كمية لاروزا في دمك.</p><p dir="RTL" style="text-align:justify">&nbsp;</p><p dir="RTL" style="text-align:justify"><strong>تأثير لاروزا على القيادة واستخدام الآلات</strong></p><p dir="RTL" style="text-align:justify">لا تقم بالقيادة، تشغيل الآلات الثقيلة أو القيام بأنشطة أخرى خطيرة حتى تعرف مدى تأثير لاروزا عليك. قد يشعرك لاروزا بالنعاس.</p><p dir="RTL" style="text-align:justify">&nbsp;</p><p dir="RTL" style="text-align:justify"><strong>الحمل والرضاعة</strong></p><p dir="RTL" style="text-align:justify">قبل تناول لاروزا، أخبري مقدم الرعاية الصحية إذا كنتِ:</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; حاملاً أو تخططين لحدوث حمل. من غير المعروف ما إذا كان لوراسيدون سيضر بجنينك. تحدثي مع مقدم الرعاية الصحية حول المخاطر التي يتعرض لها جنينك إذا كنتِ تتناولين لوراسيدون خلال فترة الحمل.</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; أخبري مقدم الرعاية الصحية في حال حدوث حمل أو إذا كنتِ تعتقدين بأنك حاملاً أثناء العلاج بلاروزا</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; تقومين بالرضاعة الطبيعية أو تخططين للرضاعة الطبيعية. من غير المعروف ما إذا كان لوراسيدون ينتقل إلى حليب الثدي. تحدثي مع مقدم الرعاية الصحية عن أفضل طريقة لتغذية طفلك أثناء العلاج بلوراسيدون.</p><p dir="RTL" style="text-align:justify"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:justify"><strong>يحتوى لاروزا على لاكتوز أحادي الماء</strong><strong>.</strong></p><p dir="RTL" style="text-align:justify">يحتوى لاروزا على لاكتوز أحادي الماء.</p><p dir="RTL" style="text-align:justify">يحتوي كل 20 ملغم قرص مغطى بطبقة رقيقة على 31.80 ملغم لاكتوز أحادي الماء.</p><p dir="RTL" style="text-align:justify">يحتوي كل 40 ملغم قرص مغطى بطبقة رقيقة على 63.60 ملغم لاكتوز أحادي الماء.</p><p dir="RTL" style="text-align:justify">يحتوي كل 80 ملغم قرص مغطى بطبقة رقيقة على 127.20 ملغم لاكتوز أحادي الماء.</p><p dir="RTL" style="text-align:justify">يحتوي كل 120 ملغم قرص مغطى بطبقة رقيقة على 190.80 ملغم لاكتوز أحادي الماء.</p><p dir="RTL" style="text-align:justify">إذا أخبرك طبيبك بأنه لديك عدم تحمل لبعض السكريات، فاتصل بطبيبك قبل تناول هذا الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; تناول لاروزا تماماً كما أخبرك مقدم الرعاية الصحية. لا تغير الجرعة أو تتوقف عن تناول لاروزا دون استشارة مقدم الرعاية الصحية أولاً.</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; قم بتناول لاروزا عن طريق الفم، مع الطعام (على الأقل 350 سعرة حرارية).</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; إذا تناولت الكثير من لاروزا، اتصل بمقدم الرعاية الصحية أو مركز مراقبة السموم أو توجه إلى أقرب وحدة طوارئ في المستشفى على الفور.</p><p dir="RTL" style="text-align:justify">&nbsp;</p><p dir="RTL" style="text-align:justify"><strong>ما الذي يجب عليّ</strong><strong> </strong><strong>أن أتجنبه أثناء تناول لاروزا</strong></p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; لا تقم بالقيادة، تشغيل الآلات الثقيلة أو القيام بأنشطة أخرى خطيرة حتى تعرف مدى تأثير لاروزا عليك. قد يشعرك لاروزا بالنعاس.</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; تجنب تناول الجريب فروت أو شرب عصير الجريب فروت أثناء العلاج بلاروزا. قد يؤثر الجريب فروت وعصير الجريب فروت على كمية لاروزا في دمك.</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; تجنب أن تصاب بسخونة عالية أو تصاب بالجفاف أثناء العلاج بلاروزا.</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; تجنب ممارسة التمارين الرياضة كثيراً.</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; أثناء الطقس الحار، عليك البقاء بالداخل في مكان بارد إن أمكن.</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; ابق بعيداً عن الشمس.</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; تجنب ارتداء الكثير من الملابس أو الملابس الثقيلة.</p><p style="text-align:justify">اشرب الكثير من المياه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify"><strong>يمكن أن يسبب لوراسيدون آثاراً جانبية خطيرة، تشمل</strong><strong>: </strong></p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; السكتة الدماغية (مشاكل دماغية وعائية) لدى كبار السن المصابين بالذهان المرتبط &nbsp;بالخرف والذي قد يؤدي إلى الوفاة.</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; المتلازمة الخبيثة للأدوية المضادة للذهان وهي حالة خطيرة يمكن أن تؤدي إلى الوفاة. اتصل بمقدم الرعاية الصحية أو توجه إلى أقرب وحدة طوارئ في المستشفى على الفور إذا ظهرت لديك جميع الأعراض والعلامات التالية للمتلازمة الخبيثة للأدوية المضادة للذهان أو بعض منها:</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; الحمى الشديدة&nbsp;</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; تصلب العضلات&nbsp;</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; الارتباك</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; زيادة التعرق</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; تغيّرات في التنفس، معدل ضربات القلب، وضغط الدم</p><p dir="RTL" style="text-align:justify"><em>&middot;&nbsp;&nbsp;&nbsp; </em>حركات جسدية غير مُتحكم بها (خلل الحركة المتأخر). قد يتسبب لاروزا في أداء حركات لا يمكنك التحكم بها في وجهك، لسانك، أو أجزاء أخرى من الجسم. قد لا يزول خلل الحركة المتأخر حتى إذا توقفت عن تناول لاروزا. قد يبدأ كذلك خلل الحركة المتأخر بعد التوقف عن تناول لاروزا.</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; مشاكل متعلقة بالأيض مثل:</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; ارتفاع السكر في الدم (فرط سكر الدم) ومرض السكري. قد تحدث زيادة في نسبة السكر في الدم لدى بعض الأشخاص الذين يتناولون لاروزا. قد يؤدي الارتفاع الشديد لنسبة السكر في الدم إلى غيبوبة أو الوفاة. إذا كنت تعاني من مرض السكري أو تعاني من عوامل التعرض لخطر الإصابة بمرض السكري (مثل فرط الوزن أو يوجد لديك تاريخ عائلي من مرض السكري)، يجب على مقدم الرعاية الصحية أن يفحص نسبة السكر في الدم لديك قبل البدء في تناول لاروزا وأثناء تناوله.</p><p dir="RTL" style="text-align:justify">اتصل بمقدم الرعاية الصحية إذا ظهرت لديك أي من هذه الأعراض لارتفاع السكر في الدم أثناء العلاج بلاروزا:</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; الشعور بعطش شديد</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; الحاجة إلى التبول أكثر من المعتاد&nbsp;</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; الشعور بالجوع الشديد</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; الشعور بالضعف أو التعب</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; الشعور بغثيان في معدتك</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; الشعور بالارتباك، أو تنبعث من نفسك رائحة فواكه &nbsp;</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; زيادة مستويات الدهون (الكوليسترول والدهون الثلاثية) في دمك.</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; زيادة في الوزن. يجب أن تفحص أنت ومقدم الرعاية الصحية الخاص بك وزنك بانتظام أثناء العلاج بلاروزا.</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; زيادة مستويات البرولاكتين في دمك (فرط برولاكتين الدم). قد يقوم مقدم الرعاية الصحية الخاص بك بإجراء فحوصات للدم للتحقق من مستويات البرولاكتين أثناء العلاج بلاروزا. أخبر مقدم الرعاية الصحية الخاص بك إذا ظهرت لديك أي من علامات فرط برولاكتين الدم التالية:</p><p dir="RTL" style="text-align:justify"><em>الإناث</em><em>:</em></p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; غياب الدورة الشهرية</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; إفراز حليب الثدي عندما لا تكونين مرضعة</p><p dir="RTL" style="text-align:justify"><em>الذكور</em><em>:</em></p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; مشاكل في حدوث الانتصاب أو الحفاظ عليه (ضعف الانتصاب)</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; تضخم الثديين (تثدي الرجل)</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء. قد يقوم مقدم الرعاية الصحية الخاص بك بإجراء فحوصات للدم خلال الشهور القليلة الأولى من العلاج بلاروزا</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم (انخفاض ضغط الدم الانتصابي). قد تشعر بدوار أو قد يغمى عليك عندما تقف سريعاً من وضع الجلوس أو الاستلقاء.</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; السقوط. قد يجعلك لاروزا تشعر بالنعاس أو الدوخة، قد يسبب انخفاضاً في ضغط الدم لديك عند تغيير وضعيتك (انخفاض ضغط الدم الانتصابي) ويمكنه إبطاء مهاراتك التفكيرية والحركية وهو ما قد يؤدي إلى السقوط الذي يمكن أن يسبب كسوراً أو إصابات أخرى.</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; نوبات الصرع (التشنجات)</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; مشاكل في التحكم في درجة حرارة جسمك، بحيث تشعر بالدفء الشديد. انظر &quot;ما الذي يجب عليّ أن أتجنبه أثناء تناول لاروزا&quot;.</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; الهوس أو الهوس الخفيف (نوبات الهوس) لدى الأشخاص الذين لديهم تاريخ من اضطراب ثنائي القطب. قد تشمل الأعراض:</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; زيادة كبيرة في الطاقة</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; مشاكل شديدة في النوم</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; أفكار مندفعة</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; سلوك متهور</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; أفكار مبالغ فيها غير اعتيادية</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; تهيج أو سعادة مفرطة</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; التحدث أكثر أو أسرع من المعدل الطبيعي</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; صعوبة في البلع</p><p dir="RTL" style="text-align:justify"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:justify"><strong>تشمل الآثار الجانبية الأكثر شيوعاً للوراسيدون لدى البالغين</strong><strong>: </strong></p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; البالغين المصابين بانفصام الشخصية:</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; النوم أو النعاس</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; التململ والشعور بأنك بحاجة إلى التحرك في الأرجاء (تعذر الجلوس)</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; صعوبة في الحركة، بطء في الحركة، تصلب العضلات، أو الرعاش</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; الأطفال من 13 إلى 17 عام المصابين بانفصام الشخصية</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; النوم أو النعاس</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; التململ والشعور بأنك بحاجة إلى التحرك في الأرجاء (تعذر الجلوس)</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; صعوبة في الحركة، بطء في الحركة، تصلب العضلات، أو الرعاش</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; سيلان الأنف</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; البالغين المصابين باضطراب ثنائي القطب</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; التململ والشعور بأنك بحاجة إلى التحرك في الأرجاء (تعذر الجلوس)</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; صعوبة في الحركة، بطء في الحركة، تصلب العضلات، أو الرعاش</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; النوم أو النعاس</p><p dir="RTL" style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; الأطفال من 10 أعوام إلى 17 عام المصابين باضطراب ثنائي القطب</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; زيادة الوزن</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp; مشاكل في النوم (أرق)&nbsp;</p><p dir="RTL" style="text-align:justify">هذه ليست كل الآثار الجانبية المحتملة للوراسيدون.</p><p dir="RTL" style="text-align:justify">اتصل بطبيبك للحصول على استشارة طبية بشأن الآثار الجانبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL" style="text-align:justify">لا يحفظ عند درجة حرارة أعلى من 30&deg; مئوية.</p><p dir="RTL" style="text-align:justify">يحفظ داخل العبوة الأصلية.</p><p dir="RTL" style="text-align:justify">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية. يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL" style="text-align:justify">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p style="text-align:justify">لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. اتبع هذه الإجراءات للحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">المادة الفعّالة هي هيدروكلوريد اللوراسيدون.</p><p dir="RTL" style="text-align:justify">يحتوي كل قرص مغطى بطبقة رقيقة من لاروزا 20 ملغم قرص مغطى بطبقة رقيقة على 20 ملغم هيدروكلوريد اللوراسيدون.</p><p dir="RTL" style="text-align:justify">يحتوي كل قرص مغطى بطبقة رقيقة من لاروزا 40 ملغم قرص مغطى بطبقة رقيقة على 40 ملغم هيدروكلوريد اللوراسيدون.</p><p dir="RTL" style="text-align:justify">يحتوي كل قرص مغطى بطبقة رقيقة من لاروزا 80 ملغم قرص مغطى بطبقة رقیقة على 80 ملغم هيدروكلوريد اللوراسيدون.</p><p dir="RTL" style="text-align:justify">يحتوي كل قرص مغطى بطبقة رقيقة من لاروزا 120 ملغم قرص مغطى بطبقة رقيقة على 120 ملغم هيدروكلوريد اللوراسيدون.</p><p dir="RTL" style="text-align:justify">المواد الأخرى المستخدمة في التركيبة التصنيعية هي لاكتوز أحادي الماء، مانيتول، النشا المعدّل، كروسكارميلوز الصوديوم، بوڤيدون، حمض الستريك اللامائي، ستيارات المغنيسيوم وأوبادري أبيض 03B28796 (هيبروميللوز، ثاني أكسيد التيتانيوم ومتعدد إيثيلين الغليكول).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">لاروزا 20 ملغم أقراص مغطاة بطبقة رقيقة هي أقراص دائرية الشكل لونها أبيض إلى أبيض عاجي، منقوش على جهة واحدة L1 وفارغة من الجهة الأخرى معبأة في أشرطة من الألومينيوم.</p><p dir="RTL" style="text-align:justify">لاروزا 40 ملغم أقراص مغطاة بطبقة رقيقة هي أقراص دائرية الشكل لونها أبيض إلى أبيض عاجي، منقوش على جهة واحدة L2 وفارغة من الجهة الأخرى معبأة في أشرطة من الألومينيوم.</p><p dir="RTL" style="text-align:justify">لاروزا 80 ملغم أقراص مغطاة بطبقة رقيقة هي أقراص بيضاوية الشكل لونها أبيض إلى أبيض عاجي، منقوش على جهة واحدة L3 وفارغة من الجهة الأخرى معبأة في أشرطة من الألومينيوم.</p><p dir="RTL" style="text-align:justify">لاروزا 120 ملغم أقراص مغطاة بطبقة رقيقة هي أقراص بيضاوية الشكل لونها أبيض إلى أبيض عاجي، منقوش على جهة واحدة L4 وفارغة من الجهة الأخرى معبأة في أشرطة من الألومينيوم.</p><p dir="RTL" style="text-align:justify">حجم العبوة: 30 قرص مغطى بطبقة رقيقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify"><strong>اسم وعنوان مالك رخصة التسويق </strong></p><p dir="RTL" style="text-align:justify">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 4980170 (11-966) +<br />فاكس:&nbsp; 4980187 (11-966) +<br />البريد الإلكتروني: medical@jpi.com.sa</p><p dir="RTL" style="text-align:justify">&nbsp;</p><p dir="RTL" style="text-align:justify"><strong>الشركة المصنعة</strong></p><p dir="RTL" style="text-align:justify">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 4980170 (11-966) +<br />فاكس:&nbsp; 4980187 (11-966) +<br />البريد الإلكتروني: medical@jpi.com.sa</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 05/2019، رقم النسخة: SA1.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Laroza 80 mg Film-coated Tablets 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 80 mg lurasidone hydrochloride. 

Excipient with known effect: Lactose monohydrate.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated Tablets.

White to off white oval shaped tablets, embossed with L3 on one side and plain on other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Laroza is indicated for:</p><p style="text-align:justify">&middot; Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia.</p><p style="text-align:justify">&middot;&nbsp; Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episodes associated with bipolar I disorder (bipolar depression).</p><p style="text-align:justify">Adjunctive treatment with lithium or valproate in adult patients with major depressive episodes associated with bipolar I disorder (bipolar depression).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Schizophrenia</u></p><p><em>Adults</em></p><p>The recommended starting dose of lurasidone is 40 mg once daily. Initial dose titration is not required. Lurasidone&nbsp; &nbsp;has been shown to be effective in a dose range of 40 mg per day to 160 mg per day. The maximum recommended dose is 160 mg per day.</p><p>&nbsp;</p><p><em>Adolescents (13-17 years)</em></p><p>The recommended starting dose of lurasidone is 40 mg once daily. Initial dose titration is not required. Lurasidone has been shown to be effective in a dose range of 40 mg per day to 80 mg per day. The maximum recommended dose is 80 mg per day.</p><p>&nbsp;</p><p><u>Depressive Episodes Associated with Bipolar I Disorder</u></p><p><em>Adults</em></p><p>The recommended starting dose of lurasidone is 20 mg given once daily as monotherapy or as adjunctive therapy with lithium or valproate. Initial dose titration is not required. Lurasidone&nbsp; &nbsp;has been shown to be effective in a dose range of 20 mg per day to 120 mg per day as monotherapy or as adjunctive therapy with lithium or valproate. The maximum recommended dose, as monotherapy or as adjunctive therapy with lithium or valproate, is 120 mg per day. In the monotherapy study, the higher dose range (80 mg to 120 mg per day) did not provide additional efficacy, on average, compared to the lower dose range (20 to 60 mg per day).</p><p>&nbsp;</p><p><em>Pediatric Patients (10 &ndash; 17 years) </em></p><p>The recommended starting dose of lurasidone is 20 mg given once daily as monotherapy. Initial dose titration is not required. The dose may be increased after one week based on clinical response. Lurasidone has been shown to be effective in a dose range of 20 mg per day to 80 mg per day as monotherapy. At the end of the clinical study, most of the patients (67%) received 20 mg or 40 mg once daily. The maximum recommended dose is 80 mg per day.</p><p>The efficacy of lurasidone in the treatment of mania associated with bipolar disorder has not been established.</p><p>&nbsp;</p><p><strong>Administration Information</strong></p><p>Lurasidone should be taken with food (at least 350 calories). Administration with food substantially increases the absorption of lurasidone. Administration with food increases the AUC approximately 2-fold and increases the C<sub>max</sub> approximately 3-fold. In the clinical studies, lurasidone was administered with food.</p><p>The effectiveness of lurasidone for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies. Therefore, the physician who elects to use lurasidone for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.</p><p>&nbsp;</p><p><strong>Dose Modifications for Renal Impairment </strong></p><p>Dose adjustment is recommended in moderate (creatinine clearance: 30 to &lt;50 mL/min) and severe renal impairment (creatinine clearance &lt;30 mL/min) patients. The recommended starting dose is 20 mg per day. The dose in these patients should not exceed 80 mg per day.</p><p>&nbsp;</p><p><strong>Dose Modifications for Hepatic Impairment </strong></p><p>Dose adjustment is recommended in moderate (Child-Pugh Score = 7 to 9) and severe hepatic impairment (Child-Pugh Score = 10 to 15) patients. The recommended starting dose is 20 mg per day. The dose in moderate hepatic impairment patients should not exceed 80 mg per day and the dose in severe hepatic impairment patients should not exceed 40 mg/day.</p><p><em>&nbsp;</em></p><p><strong>Dose Modifications Due to Drug Interactions of CYP3A4 Inhibitors and CYP3A4 Inducers</strong> <em>Concomitant Use with CYP3A4 Inhibitors</em></p><p>Laroza should not be used concomitantly with a strong CYP3A4 inhibitor (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.).</p><p>If Laroza is being prescribed and a moderate CYP3A4 inhibitor (e.g. diltiazem, atazanavir, erythromycin, fluconazole, verapamil etc.) is added to the therapy, the Laroza dose should be reduced to half of the original dose level. Similarly, if a moderate CYP3A4 inhibitor is being prescribed and Laroza is added to the therapy, the recommended starting dose of Laroza is 20 mg per day, and the maximum recommended dose of Laroza is 80 mg per day.</p><p>Grapefruit and grapefruit juice should be avoided in patients taking Laroza, since these may inhibit CYP3A4 and alter Laroza concentrations.</p><p>&nbsp;</p><p><em>Concomitant Use with CYP3A4 Inducers </em></p><p>Laroza should not be used concomitantly with a strong CYP3A4 inducer (e.g., rifampin, avasimibe, St. John&rsquo;s wort, phenytoin, carbamazepine, etc.) If Laroza is used concomitantly with a moderate CYP3A4 inducer, it may be necessary to increase the Laroza dose after chronic treatment (7 days or more) with the CYP3A4 inducer.</p><p>&nbsp;</p><p><strong>Pediatric Use </strong></p><p>&middot;&nbsp;&nbsp;<em>Schizophrenia </em></p><p>The safety and effectiveness of lurasidone 40-mg/day and 80-mg/day for the treatment of schizophrenia in adolescents (13 to 17 years) was established in a 6-week, placebo-controlled clinical study in 326 adolescent patients.</p><p>The safety and effectiveness of lurasidone has not been established in pediatric patients less than 13 years of age with schizophrenia.</p><p>&nbsp;</p><p>&middot;&nbsp;<em>Bipolar Depression </em></p><p>The safety and effectiveness of lurasidone 20 to 80 mg/day for the treatment of bipolar depression in pediatric patients (10 to 17 years) was established in a 6-week, placebo-controlled clinical study in 347 pediatric patients.</p><p>The safety and effectiveness of lurasidone has not been established in pediatric patients less than 10 years of age with bipolar depression.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;<em>Irritability Associated with Autistic Disorder </em></p><p>The effectiveness of lurasidone in pediatric patients for the treatment of irritability associated with autistic disorder has not been established.</p><p>Efficacy was not demonstrated in a 6-week study evaluating lurasidone 20 mg/day and 60 mg/day for the treatment of pediatric patients 6 to 17 years of age with irritability associated with autistic disorder diagnosed by Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., Text Revision [DSM-IV-TR] criteria. The primary objective of the study as measured by improvement from Baseline in the irritability subscale of the Aberrant Behavior Checklist (ABC) at Endpoint (Week 6) was not met. A total of 149 patients were randomized to lurasidone or placebo. Vomiting occurred at a higher rate than reported in other lurasidone studies (4/49 or 8% for 20mg, 14/51 or 27% for 60mg, and 2/49 or 4% for placebo), particularly in children ages 6 to 12 (13 out of 18 patients on lurasidone with vomiting).</p><p>&nbsp;</p><p>&middot;&nbsp; <em>Juvenile animal studies </em></p><p>Adverse effects were seen on growth, physical and neurobehavioral development at doses as low as 0.2 times the MRHD based on mg/m<sup>2</sup>. Lurasidone was orally administered to rats from postnatal days 21 through 91 (this period corresponds to childhood, adolescence, and young adulthood in humans) at doses of 3, 30, and 150 (males) or 300 (females) mg/kg/day which are 0.2 to 10 times (males) and 20 times (females) the maximum recommended adult human dose (MRHD) of 160 mg/day based on mg/m<sup>2</sup>. The adverse effects included dose-dependent decreases in femoral length, bone mineral content, body and brain weights at 2 times the MRHD in both sexes, and motor hyperactivity at 0.2 and 2 times the MRHD in both sexes based on mg/m<sup>2</sup>. In females, there was a delay in attainment of sexual maturity at 2 times the MRHD, associated with decreased serum estradiol. Mortality occurred in both sexes during early post-weaning period and some of the male weanlings died after only 4 treatments at doses as low as 2 times the MRHD based on mg/m<sup>2</sup>. Histopathological findings included increased colloid in the thyroids and inflammation of the prostate in males at 10 times MRHD based on mg/m<sup>2 </sup>and mammary gland hyperplasia, increased vaginal mucification, and increased ovarian atretic follicles at doses as low as 0.2 times the MRHD based on mg/m<sup>2</sup>. Some of these findings were attributed to transiently elevated serum prolactin which was seen in both sexes at all doses. However, there were no changes at any dose level in reproductive parameters (fertility, conception indices, spermatogenesis, estrous cycle, gestation length, parturition, number of pups born). The no effect dose for neurobehavioral changes in males is 0.2 times the MHRD based on mg/m<sup>2 </sup>and could not be determined in females. The no effect dose for growth and physical development in both sexes is 0.2 times the MRHD based on mg/m<sup>2</sup>.</p><p><strong>&nbsp;</strong></p><p><strong>Geriatric Use </strong></p><p>Clinical studies with lurasidone did not include sufficient numbers of patients aged 65 and older to determine whether or not they respond differently from younger patients. In elderly patients with psychosis (65 to 85), lurasidone concentrations (20 mg/day) were similar to those in young subjects. It is unknown whether dose adjustment is necessary on the basis of age alone.</p><p>Elderly patients with dementia-related psychosis treated with lurasidone are at an increased risk of death compared to placebo. Lurasidone is not approved for the treatment of patients with dementia-related psychosis.</p><p>&nbsp;</p><p><strong>Other Specific Populations </strong></p><p>No dosage adjustment for Laroza is required on the basis of a patient&rsquo;s sex, race, or smoking status.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Known hypersensitivity to lurasidone HCl or any components in the formulation.  Angioedema has been observed with lurasidone.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.)
• Strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John’s wort, phenytoin, carbamazepine, etc.) 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Increased Mortality in Elderly Patients with Dementia-Related Psychosis</strong></p><p>Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6- to 1.7-times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were&nbsp;</p><p>varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Lurasidone is not approved for the treatment of patients with dementia-related psychosis.</p><p><strong>&nbsp;</strong></p><p><strong>Suicidal Thoughts and Behaviors in Pediatric and Young Adult Patients</strong></p><p>In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients, and over 4,400 pediatric patients, the incidence of suicidal thoughts and behaviors in pediatric and young adult patients was greater in antidepressant-treated patients than in placebo-treated patients. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1000 patients treated are provided in Table 1.</p><p>No suicides occurred in any of the pediatric studies. There were suicides in the adult studies, but the number was not sufficient to reach any conclusion about antidepressant drug effect on suicide.</p><p>&nbsp;</p><p><strong>&nbsp;Table 1: Risk Differences of the Number of Cases of Suicidal Thoughts or Behaviors in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric and Adult Patients </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Age Range</strong></p></td><td><p><strong>Drug-Placebo Difference in Number of Patients of Suicidal Thoughts or Behaviors per 1000 Patients Treated</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>Increases Compared to Placebo</strong></p></td></tr><tr><td><p>&lt;18</p></td><td><p>14 additional patients</p></td></tr><tr><td><p>18-24</p></td><td><p>5 additional patients</p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>Decreases Compared to Placebo</strong></p></td></tr><tr><td><p>25-64</p></td><td><p>1 fewer patient</p></td></tr><tr><td><p>&ge;65</p></td><td><p>6 fewer patients</p></td></tr></tbody></table><p>&nbsp;</p><p>It is unknown whether the risk of suicidal thoughts and behaviors in pediatric and young adult patients extends to longer-term use, i.e., beyond four months. However, there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression.</p><p>Monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy and at times of dosage changes. Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare provider. Consider changing the therapeutic regimen, including possibly discontinuing Laroza , in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or<em> </em>behaviors.</p><p>&nbsp;</p><p><strong>Cerebrovascular Adverse Reactions, Including Stroke in Elderly Patients with Dementia-Related Psychosis </strong></p><p>In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks), including fatalities, compared to placebo-treated subjects. Lurasidone is not approved for the treatment of patients with dementia-related psychosis.</p><p>&nbsp;</p><p><strong>Neuroleptic Malignant Syndrome </strong></p><p>A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including lurasidone. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability. Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.</p><p>If NMS is suspected, immediately discontinue Laroza and provide intensive symptomatic treatment and monitoring</p><p><strong>&nbsp;</strong></p><p><strong>Tardive Dyskinesia </strong></p><p>Tardive dyskinesia is a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements that can develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.</p><p>The risk of developing tardive dyskinesia and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses or may even arise after discontinuation of treatment.</p><p>The syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.</p><p>Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.</p><p>Given these considerations, Laroza should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.</p><p>If signs and symptoms of tardive dyskinesia appear in a patient on Laroza, drug discontinuation should be considered. However, some patients may require treatment with Laroza despite the presence of the syndrome.</p><p>&nbsp;</p><p><strong>Metabolic Changes </strong></p><p>Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain. While all of the drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile.</p><p>&nbsp;</p><p><em><u>Hyperglycemia and Diabetes Mellitus </u></em></p><p>Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse events is not completely understood. However, epidemiological studies suggest an increased risk of hyperglycemia-related adverse events in patients treated with the atypical antipsychotics.</p><p>Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;<em>Schizophrenia </em></p><p><u>Adults </u></p><p>Pooled data from short-term, placebo-controlled schizophrenia studies are presented in Table 2.</p><p>&nbsp;</p><p><strong>Table 2:&nbsp; Change in Fasting Glucose in Adult Schizophrenia Studies</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="7"><p><strong>Lurasidone</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>Placebo</strong></p></td><td><p><strong>20 mg/day</strong></p></td><td><p><strong>40 mg/day</strong></p></td><td><p><strong>80 mg/day</strong></p></td><td><p><strong>120 mg/day</strong></p></td><td><p><strong>160 mg/day</strong></p></td></tr><tr><td colspan="7"><p><strong>Mean Change from Baseline (</strong><strong>mg/dL)</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>n=680</strong></p></td><td><p><strong>n=71</strong></p></td><td><p><strong>n=478</strong></p></td><td><p><strong>n=508</strong></p></td><td><p><strong>n=283</strong></p></td><td><p><strong>n=113</strong></p></td></tr><tr><td><p>Serum Glucose</p></td><td><p>-0.0</p></td><td><p>-0.6</p></td><td><p>+2.6</p></td><td><p>-0.4</p></td><td><p>+2.5</p></td><td><p>+2.5</p></td></tr><tr><td colspan="7"><p><strong>Proportion of Patients with Shifts to &ge; 126 mg/dL</strong></p></td></tr><tr><td><p>Serum Glucose (&ge; 126 mg/dL)</p></td><td><p>8.3% (52/628)</p></td><td><p>11.7</p><p>(7/60)</p></td><td><p>12.7% (57/449)</p></td><td><p>6.8%</p><p>(32/472)</p></td><td><p>10.0% (26/260)</p></td><td><p>5.6%</p><p>(6/108)</p></td></tr></tbody></table><p>&nbsp;</p><p>In the uncontrolled, longer-term schizophrenia studies (primarily open-label extension studies), lurasidone&nbsp; &nbsp;was associated with a mean change in glucose of +1.8 mg/dL at week 24 (n=355), +0.8 mg/dL at week 36 (n=299) and +2.3 mg/dL at week 52 (n=307).</p><p>&nbsp;</p><p><u>Adolescents </u></p><p>In studies of adolescents and adults with schizophrenia, changes in fasting glucose were similar. In the short-term, placebo-controlled study of adolescents, fasting serum glucose mean values were -1.3 for placebo (n=95), +0.1 for 40mg (n=90), and +1.8 for 80mg (n=92).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Bipolar Depression </em></strong></p><p><u>Adults</u></p><p><em>Monotherapy </em></p><p>Data from the adult short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study are presented in Table 3.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Table 3: Change in Fasting Glucose in the Adult Monotherapy Bipolar Depression Study </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4"><p><strong>Lurasidone</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>Placebo</strong></p></td><td><p><strong>20 to 60 mg/day</strong></p></td><td><p><strong>80 to 120 mg/day</strong></p></td></tr><tr><td colspan="4"><p><strong>Mean Change from Baseline (mg/dL)</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>n=148</strong></p></td><td><p><strong>n=140</strong></p></td><td><p><strong>n=143</strong></p></td></tr><tr><td><p>Serum Glucose</p></td><td><p>+1.8</p></td><td><p>-0.8</p></td><td><p>+1.8</p></td></tr><tr><td colspan="4"><p><strong>Proportion of Patients with Shifts to &ge; 126 g/dL</strong></p></td></tr><tr><td><p>Serum Glucose (&ge; 126 mg/dL)</p></td><td><p>4.3%</p><p>(6/141)</p></td><td><p>2.2%</p><p>(3/138)</p></td><td><p>6.4%</p><p>(9/141)</p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Patients were randomized to flexibly dosed lurasidone 20 to 60 mg/day, lurasidone 80 to 120 mg/day, or placebo</p><p>In the uncontrolled, open-label, longer-term bipolar depression study, patients who received lurasidone as monotherapy in the short-term study and continued in the longer-term study, had a mean change in glucose of +1.2 mg/dL at week 24 (n=129).</p><p>&nbsp;</p><p><em>Adjunctive Therapy with Lithium or Valproate </em></p><p>Data from the adult short-term, flexible-dosed, placebo-controlled adjunctive therapy bipolar depression studies are presented in Table 4.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Table 4: Change in Fasting Glucose in the Adult Adjunctive Therapy Bipolar Depression Studies</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>Placebo</strong></p></td><td><p><strong>Lurasidone</strong></p><p><strong>20 to 120 mg/day</strong></p></td></tr><tr><td colspan="3"><p><strong>Mean Change from Baseline (mg/dL)</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>n=302</strong></p></td><td><p><strong>n=319</strong></p></td></tr><tr><td><p>Serum Glucose</p></td><td><p>-0.9</p></td><td><p>+1.2</p></td></tr><tr><td colspan="3"><p><strong>Proportion of Patients with Shifts to &ge; 126 mg/Dl</strong></p></td></tr><tr><td><p>Serum Glucose (&ge; 126 mg/dL)</p></td><td><p>1.0%</p><p>(3/290)</p></td><td><p>1.3%</p><p>(4/316)</p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Patients were randomized to flexibly dosed lurasidone 20 to 120 mg/day or placebo as adjunctive therapy with lithium or valproate.</p><p>In the uncontrolled, open-label, longer-term bipolar depression study, patients who received lurasidone as adjunctive therapy with either lithium or valproate in the short-term study and continued in the longer-term study, had a mean change in glucose of +1.7 mg/dL at week 24 (n=88).</p><p>&nbsp;</p><p><u>Pediatric Patients (10 to 17 years) </u></p><p>In studies of pediatric patients 10 to 17 years and adults with bipolar depression, changes in fasting glucose were similar. In the 6-week, placebo-controlled study of pediatric patients with bipolar depression, mean change in fasting glucose was +1.6 mg/dL for lurasidone 20 to 80 mg/day (n=145) and -0.5 mg/dL for placebo (n=145).</p><p>&nbsp;</p><p><em><u>Dyslipidemia </u></em></p><p>Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.</p><p>&nbsp;</p><p>&middot;&nbsp;<em>Schizophrenia </em></p><p><u>Adults </u></p><p>Pooled data from short-term, placebo-controlled schizophrenia studies are presented in Table 5: Change in Fasting Lipids in Adult Schizophrenia Studies.</p><p>&nbsp;</p><p><strong>Table 5: Change in Fasting Lipids in Adult Schizophrenia Studies</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="7"><p><strong>Lurasidone</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>Placebo</strong></p></td><td><p><strong>20 mg/day</strong></p></td><td><p><strong>40 mg/day</strong></p></td><td><p><strong>80 mg/day</strong></p></td><td><p><strong>120 mg/day</strong></p></td><td><p><strong>160 mg/day</strong></p></td></tr><tr><td colspan="7"><p><strong>Mean Change from Baseline (mg/dL)</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>n=660</strong></p></td><td><p><strong>n=71</strong></p></td><td><p><strong>n=466</strong></p></td><td><p><strong>n=499</strong></p></td><td><p><strong>n=268</strong></p></td><td><p><strong>n=115</strong></p></td></tr><tr><td><p>Total Cholesterol</p></td><td><p>-5.8</p></td><td><p>-12.3</p></td><td><p>-5.7</p></td><td><p>-6.2</p></td><td><p>-3.8</p></td><td><p>-6.9</p></td></tr><tr><td><p>Triglycerides</p></td><td><p>-13.4</p></td><td><p>-29.1</p></td><td><p>-5.1</p></td><td><p>-13.0</p></td><td><p>-3.1</p></td><td><p>-10.6</p></td></tr><tr><td colspan="7"><p><strong>Proportion of Patients with Shifts</strong></p></td></tr><tr><td colspan="7"><p><strong>Mean Change from Baseline (mg/dL)</strong></p></td></tr><tr><td><p>Total Cholesterol (&ge; 240 mg/dL)</p></td><td><p>5.3% (30/571)</p></td><td><p>13.8% (8/58)</p></td><td><p>6.2% (25/402)</p></td><td><p>5.3% (23/434)</p></td><td><p>3.8%</p><p>(9/238)</p></td><td><p>4.0%</p><p>(4/101)</p></td></tr><tr><td><p>Triglycerides (&ge; 200 mg/dL)</p></td><td><p>10.1% (53/526)</p></td><td><p>14.3%</p><p>(7/49)</p></td><td><p>10.8% (41/379)</p></td><td><p>6.3% (25/400)</p></td><td><p>10.5% (22/209)</p></td><td><p>7.0%</p><p>(7/100)</p></td></tr></tbody></table><p>In the uncontrolled, longer-term schizophrenia studies (primarily open-label extension studies), lurasidone&nbsp; &nbsp;was associated with a mean change in total cholesterol and triglycerides of -3.8 (n=356) and -15.1 (n=357) mg/dL at week 24, -3.1 (n=303) and -4.8 (n=303) mg/dL at week 36 and -2.5 (n=307) and -6.9 (n=307) mg/dL at week 52, respectively.</p><p>&nbsp;</p><p><u>Adolescents</u></p><p>In the adolescent short-term, placebo-controlled study, fasting serum cholesterol mean values were -9.6 for placebo (n=95), -4.4 for 40mg (n=89), and +1.6 for 80mg (n=92), and fasting serum triglyceride mean values were +0.1 for placebo (n=95), -0.6 for 40mg (n=89), and +8.5 for 80mg (n=92).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Bipolar Depression </em></strong></p><p><u>Adults</u></p><p><em>Monotherapy </em></p><p>Data from the adult short-term, flexible-dosed, placebo-controlled, monotherapy bipolar depression study are presented in Table 6.</p><p><strong>&nbsp;</strong></p><p><strong>Table 6: Change in Fasting Lipids in the Adults Monotherapy Bipolar Depression Study </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4"><p><strong>Lurasidone</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>Placebo</strong></p></td><td><p><strong>20 to 60 mg/day</strong></p></td><td><p><strong>80 to 120 mg/day</strong></p></td></tr><tr><td colspan="4"><p><strong>Mean Change from Baseline (mg/dL)</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>n=147</strong></p></td><td><p><strong>n=140</strong></p></td><td><p><strong>n=144</strong></p></td></tr><tr><td><p>Total cholesterol</p></td><td><p>-3.2</p></td><td><p>+1.2</p></td><td><p>-4.6</p></td></tr><tr><td><p>Triglycerides</p></td><td><p>+6.0</p></td><td><p>+5.6</p></td><td><p>+0.4</p></td></tr><tr><td colspan="4"><p><strong>Proportion of Patients with Shifts</strong></p></td></tr><tr><td><p>Total cholesterol (&ge; 240 mg/dL)</p></td><td><p>4.2%</p><p>(5/118)</p></td><td><p>4.4%</p><p>(5/113)</p></td><td><p>4.4%</p><p>(5/114)</p></td></tr><tr><td><p>Triglycerides (&ge; 200 mg/dL)</p></td><td><p>4.8%</p><p>(6/126)</p></td><td><p>10.1%</p><p>(12/119)</p></td><td><p>9.8%</p><p>(12/122)</p></td></tr></tbody></table><p>&nbsp;</p><p>Patients were randomized to flexibly dosed lurasidone 20 to 60 mg/day, lurasidone 80 to 120 mg/day, or placebo</p><p>In the uncontrolled, open-label, longer-term bipolar depression study, patients who received lurasidone as monotherapy in the short-term and continued in the longer-term study had a mean change in total cholesterol and triglycerides of -0.5 mg/dL (n=130) and -1.0 mg/dL (n=130) at week 24, respectively.</p><p>&nbsp;</p><p><em>Adjunctive Therapy with Lithium or Valproate </em></p><p>Data from the adult short-term, flexible-dosed, placebo-controlled, adjunctive therapy bipolar depression studies are presented in Table 7.</p><p><strong>Table 7: Change in Fasting Lipids in the Adult Adjunctive Therapy Bipolar Depression Studies</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td>&nbsp;</td><td><p><strong>Placebo</strong></p></td><td><p><strong>Lurasidone</strong></p><p><strong>20 to 120 mg/day</strong></p></td></tr><tr><td colspan="3"><p><strong>Mean Change from Baseline (mg/dL)</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>n=303</strong></p></td><td><p><strong>n=321</strong></p></td></tr><tr><td><p>Total cholesterol</p></td><td><p>-2.9</p></td><td><p>-3.1</p></td></tr><tr><td><p>Triglycerides</p></td><td><p>-4.6</p></td><td><p>+4.6</p></td></tr><tr><td colspan="3"><p><strong>Proportion of Patients with Shifts</strong></p></td></tr><tr><td><p>Total cholesterol</p><p>(&ge; 240 mg/dL)</p></td><td><p>5.7%</p><p>(15/263)</p></td><td><p>5.4%</p><p>(15/276)</p></td></tr><tr><td><p>Triglycerides</p><p>(&ge; 200 mg/dL)</p></td><td><p>8.6%</p><p>(21/243)</p></td><td><p>10.8%</p><p>(28/260)</p></td></tr></tbody></table><p>&nbsp;</p><p>Patients were randomized to flexibly dosed lurasidone 20 to 120 mg/day or placebo as adjunctive therapy with lithium or valproate.</p><p>In the uncontrolled, open-label, longer-term bipolar depression study, patients who received lurasidone, as adjunctive therapy with either lithium or valproate in the short-term study and continued in the longer-term study, had a mean change in total cholesterol and triglycerides of -0.9 (n=88) and +5.3 (n=88) mg/dL at week 24, respectively.</p><p>&nbsp;</p><p><u>Pediatric Patients (10 to 17 years) </u></p><p>In the 6-week, placebo-controlled bipolar depression study with pediatric patients 10 to 17 years, mean change in fasting cholesterol was -6.3 mg/dL for lurasidone 20 to 80 mg/day (n=144) and</p><p>1.4 mg/dL for placebo (n=145), and mean change in fasting triglyceride was -7.6 mg/dL for lurasidone 20 to 80 mg/day (n=144) and +5.9 mg/dL for placebo (n=145).</p><p>&nbsp;</p><p><em><u>Weight Gain</u></em></p><p>Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.</p><p>&nbsp;</p><p>&middot;&nbsp;<em>Schizophrenia</em></p><p><u>Adults</u></p><p>Pooled data from short-term, placebo-controlled schizophrenia studies are presented in Table 8. The mean weight gain was +0.43 kg for lurasidone -treated patients compared to -0.02 kg for placebo-treated patients. Change in weight from baseline for olanzapine was +4.15 kg and for quetiapine extended-release was +2.09 kg in Studies 3 and 5, respectively. The proportion of patients with a &ge;7% increase in body weight (at Endpoint) was 4.8% for lurasidone -treated patients and 3.3% for placebo-treated patients.</p><p>&nbsp;</p><p><strong>Table 8: Mean Change in Weight (kg) from Baseline in Adult Schizophrenia Studies</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="7"><p><strong>Lurasidone</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>Placebo (n=696)</strong></p></td><td><p><strong>20 mg/day (n=71)</strong></p></td><td><p><strong>40 mg/day (n=484)</strong></p></td><td><p><strong>80 mg/day (n=526)</strong></p></td><td><p><strong>120 mg/day (n=291)</strong></p></td><td><p><strong>160 mg/day (n=114</strong></p></td></tr><tr><td><p>All Patients</p></td><td><p>-0.02</p></td><td><p>-0.15</p></td><td><p>+0.22</p></td><td><p>+0.54</p></td><td><p>+0.68</p></td><td><p>+0.60</p></td></tr></tbody></table><p>&nbsp;</p><p>In the uncontrolled, longer-term schizophrenia studies (primarily open-label extension studies), lurasidone was associated with a mean change in weight of -0.69 kg at week 24 (n=755), -0.59 kg at week 36 (n=443) and -0.73 kg at week 52 (n=377).</p><p>&nbsp;</p><p><u>Adolescents</u></p><p>Data from the short-term, placebo-controlled adolescent schizophrenia study are presented in Table 9. The mean change in weight gain was +0.5 kg for lurasidone -treated patients compared to +0.2 kg for placebo-treated patients. The proportion of patients with a &ge;7% increase in body weight (at Endpoint) was 3.3% for lurasidone-treated patients and 4.5% for placebo-treated patients.</p><p>&nbsp;</p><p><strong>Table 9: Mean Change in Weight (kg) from Baseline in the Adolescent Schizophrenia Study</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td colspan="2"><p><strong>Lurasidone</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>(n=111)</strong></p></td><td><p><strong>40 mg/day</strong></p><p><strong>(n=109)</strong></p></td><td><p><strong>80 mg/day</strong></p><p><strong>(n=104)</strong></p></td></tr><tr><td><p>All Patients</p></td><td><p>+0.2</p></td><td><p>+0.3</p></td><td><p>+0.7</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;<strong><em>Bipolar Depression</em></strong></p><p><u>Adults</u></p><p><em>Monotherapy</em></p><p>Data from the adult short-term, flexible-dosed, placebo-controlled monotherapy bipolar depression study are presented in Table 10. The mean change in weight gain was +0.29 kg for lurasidone-treated patients compared to -0.04 kg for placebo-treated patients. The proportion of patients with a &ge;7% increase in body weight (at Endpoint) was 2.4% for lurasidone -treated patients and 0.7% for placebo-treated patients.</p><p>&nbsp;</p><p><strong>Table 10: Mean Change in Weight (kg) from Baseline in the Adult Monotherapy Bipolar Depression Study </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td colspan="2"><p><strong>Lurasidone</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>Placebo </strong></p><p><strong>(n=151)</strong></p></td><td><p><strong>20 to 60 mg/day (n=143)</strong></p></td><td><p><strong>80 to 120 mg/day (n=147)</strong></p></td></tr><tr><td><p>All Patients</p></td><td><p>-0.04</p></td><td><p>+0.56</p></td><td><p>+0.02</p></td></tr></tbody></table><p>&nbsp;</p><p>Patients were randomized to flexibly dosed lurasidone 20 to 60 mg/day, lurasidone 80 to 120 mg/day, or placebo</p><p>In the uncontrolled, open-label, longer-term bipolar depression study, patients who received lurasidone as monotherapy in the short-term and continued in the longer-term study had a mean change in weight of -0.02 kg at week 24 (n=130).</p><p>&nbsp;</p><p><em>Adjunctive Therapy with Lithium or Valproate</em></p><p>Data from the adult short-term, flexible-dosed, placebo-controlled adjunctive therapy bipolar depression studies are presented in Table 11. The mean change in weight gain was +0.11 kg for lurasidone-treated patients compared to +0.16 kg for placebo-treated patients. The proportion of patients with a &ge;7% increase in body weight (at Endpoint) was 3.1% for lurasidone -treated patients and 0.3% for placebo-treated patients.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Table 11: Mean Change in Weight (kg) from Baseline in the Adult Adjunctive Therapy Bipolar Depression Studies&nbsp;&nbsp; </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Placebo </strong></p><p><strong>(n=307)</strong></p></td><td><p><strong>Lurasidone</strong></p><p><strong>20 to 120 mg/day (n=327)</strong></p></td></tr><tr><td><p>All Patients</p></td><td><p>+0.16</p></td><td><p>+0.11</p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Patients were randomized to flexibly dosed lurasidone 20 to 120 mg/day or placebo as adjunctive therapy with lithium or valproate.</p><p>In the uncontrolled, open-label, longer-term bipolar depression study, patients who were treated with lurasidone, as adjunctive therapy with either lithium or valproate in the short-term and continued in the longer-term study, had a mean change in weight of +1.28 kg at week 24 (n=86).</p><p>&nbsp;</p><p><u>Pediatric Patients (10 to 17 years) </u></p><p>Data from the 6-week, placebo-controlled bipolar depression study in patients 10 to 17 years are presented in Table 12. The mean change in weight gain was +0.7 kg for lurasidone-treated patients compared to +0.5 kg for placebo-treated patients. The proportion of patients with a &ge;7% increase in body weight (at Endpoint) was 4.0% for lurasidone -treated patients and 5.3% for placebo-treated patients.</p><p>&nbsp;</p><p><strong>Table 12: Mean Change in Weight (kg) from Baseline in the Bipolar Depression Study in Pediatric Patients (10 to 17 years) </strong></p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Placebo </strong></p><p><strong>(n=170)</strong></p></td><td><p><strong>Lurasidone</strong></p><p><strong>20 to 80 mg/day (n=175)</strong></p></td></tr><tr><td><p>All Patients</p></td><td><p>+0.5</p></td><td><p>+0.7</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Hyperprolactinemia </strong></p><p>As with other drugs that antagonize dopamine D2 receptors, lurasidone elevates prolactin levels.</p><p>Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotrophin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported with prolactin-elevating compounds. Long-standing hyperprolactinemia, when associated with hypogonadism, may lead to decreased bone density in both female and male patients (4.8 Undesirable Effects).</p><p>Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent <em>in vitro</em>, a factor of potential importance if the prescription of these drugs is considered in a patient with previously detected breast cancer. As is common with compounds which increase prolactin release, an increase in mammary gland neoplasia was observed in a carcinogenicity study conducted with lurasidone in rats and mice. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans, but the available evidence is too limited to be conclusive.</p><p><em>&nbsp;</em></p><p>&middot;&nbsp;<em>Schizophrenia </em></p><p><u>Adults </u></p><p>In short-term, placebo-controlled schizophrenia studies, the median change from baseline to endpoint in prolactin levels for lurasidone-treated patients was +0.4 ng/mL and was -1.9 ng/mL in the placebo-treated patients. The median change from baseline to endpoint for males was +0.5 ng/mL and for females was -0.2 ng/mL. Median changes for prolactin by dose are shown in Table 13.</p><p>&nbsp;</p><p><strong>Table 13: Median Change in Prolactin (ng/mL) from Baseline in Adult Schizophrenia Studies</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td colspan="5"><p><strong>Lurasidone</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>Placebo</strong></p></td><td><p><strong>20 mg/day</strong></p></td><td><p><strong>40 mg/day</strong></p></td><td><p><strong>80 mg/day</strong></p></td><td><p><strong>120 mg/day</strong></p></td><td><p><strong>160 mg/day</strong></p></td></tr><tr><td><p>All Patients</p></td><td><p>-1.9 (n=672)</p></td><td><p>-1.1</p><p>(n=70)</p></td><td><p>-1.4 (n=476)</p></td><td><p>-0.2 (n=495)</p></td><td><p>+3.3</p><p>(n=284)</p></td><td><p>+3.3 (n=115)</p></td></tr><tr><td><p>Females</p></td><td><p>-5.1 (n=200)</p></td><td><p>-0.7</p><p>(n=19)</p></td><td><p>-4.0 (n=149)</p></td><td><p>-0.2 (n=150)</p></td><td><p>+6.7</p><p>(n=70)</p></td><td><p>+7.1</p><p>&nbsp;(n=36)</p></td></tr><tr><td><p>Males</p></td><td><p>-1.3 (n=472)</p></td><td><p>-1.2</p><p>(n=51)</p></td><td><p>-0.7 (n=327)</p></td><td><p>-0.2 (n=345)</p></td><td><p>+3.1</p><p>&nbsp;(n=214)</p></td><td><p>+2.4</p><p>(n=79)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>The proportion of patients with prolactin elevations &ge;5&times; upper limit of normal (ULN) was 2.8% for lurasidone-treated patients and 1.0% for placebo-treated patients. The proportion of female patients with prolactin elevations &ge;5x ULN was 5.7% for lurasidone-treated patients and = 2.0% for placebo-treated female patients. The proportion of male patients with prolactin elevations &ge;5x ULN was 1.6% and 0.6% for placebo-treated male patients.</p><p>In the uncontrolled longer-term schizophrenia studies (primarily open-label extension studies), lurasidone was associated with a median change in prolactin of -0.9 ng/mL at week 24 (n=357), -5.3ng/mL at week 36 (n=190) and -2.2 ng/mL at week 52 (n=307).</p><p>&nbsp;</p><p><u>Adolescents </u></p><p>In the short-term, placebo-controlled adolescent schizophrenia study, the median change from baseline to endpoint in prolactin levels for lurasidone-treated patients was +1.1 ng/mL and was +0.1 ng/mL for placebo-treated patients. For lurasidone -treated patients, the median change from baseline to endpoint for males was +1.0 ng/mL and for females was +2.6 ng/mL. Median changes for prolactin by dose are shown in Table 14.</p><p>&nbsp;</p><p><strong>Table 14: M</strong><strong>edian Change in Prolactin (ng/mL) from Baseline in the Adolescent Schizophrenia Study</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Placebo</strong></p></td><td><p><strong>Lurasidone</strong></p><p><strong>40 mg/day</strong></p></td><td><p><strong>Lurasidone</strong></p><p><strong>80 mg/day</strong></p></td></tr><tr><td><p>All Patients</p></td><td><p>+0.10</p><p>(n=103)</p></td><td><p>+0.75</p><p>&nbsp;(n=102)</p></td><td><p>+1.20</p><p>(n=99)</p></td></tr><tr><td><p>Females</p></td><td><p>+0.70</p><p>(n=39)</p></td><td><p>+0.60</p><p>(n=42)</p></td><td><p>+4.40</p><p>&nbsp;(n=33)</p></td></tr><tr><td><p>Males</p></td><td><p>0.00</p><p>(n=64)</p></td><td><p>+0.75</p><p>&nbsp;(n=60)</p></td><td><p>+1.00</p><p>&nbsp;(n=66)</p></td></tr></tbody></table><p>&nbsp;</p><p>The proportion of patients with prolactin elevations &ge;5x ULN was 0.5% for lurasidone -treated patients and 1.0% for placebo-treated patients. The proportion of female patients with prolactin elevations &ge;5x ULN was 1.3% for lurasidone-treated patients and 0% for placebo-treated female patients. The proportion of male patients with prolactin elevations &ge;5x ULN was 0% and 1.6% for placebo-treated male patients.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;<strong><em>Bipolar Depression </em></strong></p><p><u>Adults</u></p><p><em><u>Monotherapy </u></em></p><p>The median change from baseline to endpoint in prolactin levels, in the adult short-term, flexible-dosed, placebo-controlled monotherapy bipolar depression study, was +1.7 ng/mL and +3.5 ng/mL with lurasidone 20 to 60 mg/day and 80 to 120 mg/day, respectively compared to +0.3 ng/mL with placebo-treated patients. The median change from baseline to endpoint for males was +1.5 ng/mL and for females was +3.1 ng/mL. Median changes for prolactin by dose range are shown in Table 15.</p><p>&nbsp;</p><p><strong>Table 15: Median Change in Prolactin (ng/mL) from Baseline in the Adult Monotherapy Bipolar Depression Study</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td colspan="2"><p><strong>Lurasidone</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>Placebo</strong></p></td><td><p><strong>20 to 60 mg/day</strong></p></td><td><p><strong>80 to 120 mg/day</strong></p></td></tr><tr><td><p>All Patients</p></td><td><p>+0.3</p><p>(n=147)</p></td><td><p>+1.7</p><p>(n=140)</p></td><td><p>+3.5</p><p>(n=144)</p></td></tr><tr><td><p>Females</p></td><td><p>0.0</p><p>(n=82)</p></td><td><p>+1.8</p><p>(n=78)</p></td><td><p>+5.3</p><p>(n=88)</p></td></tr><tr><td><p>Males</p></td><td><p>+0.4</p><p>(n=65)</p></td><td><p>+1.2</p><p>(n=62)</p></td><td><p>+1.9</p><p>(n=56)</p></td></tr></tbody></table><p>&nbsp;</p><p>Patients were randomized to flexibly dosed lurasidone 20 to 60 mg/day, lurasidone 80 to 120 mg/day, or placebo</p><p>The proportion of patients with prolactin elevations &ge;5x upper limit of normal (ULN) was 0.4% for lurasidone-treated patients and 0.0% for placebo-treated patients. The proportion of female patients with prolactin elevations &ge;5x ULN was 0.6% for lurasidone-treated patients and 0% for placebo-treated female patients. The proportion of male patients with prolactin elevations &ge;5x ULN was 0% and 0% for placebo-treated male patients.</p><p>In the uncontrolled, open-label, longer-term bipolar depression study, patients who were treated with lurasidone as monotherapy in the short-term and continued in the longer-term study, had a median change in prolactin of -1.15 ng/mL at week 24 (n=130).</p><p>&nbsp;</p><p><em><u>Adjunctive Therapy with Lithium or Valproate </u></em></p><p>The median change from baseline to endpoint in prolactin levels, in the adult short-term, flexible-dosed, placebo-controlled adjunctive therapy bipolar depression studies was +2.8 ng/mL with lurasidone 20 to 120 mg/day compared to 0.0 ng/mL with placebo-treated patients. The median change from baseline to endpoint for males was +2.4 ng/mL and for females was +3.2 ng/mL. Median changes for prolactin across the dose range are shown in Table 16.</p><p>&nbsp;</p><p><strong>Table 16:</strong> <strong>Median Change in Prolactin (ng/mL) from Baseline in the Adult Adjunctive Therapy Bipolar Depression Studies</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>Lurasidone</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>Placebo</strong></p></td><td><p><strong>20 to 120 mg/day</strong></p></td></tr><tr><td><p>All Patients</p></td><td><p>0.0</p><p>(n=301)</p></td><td><p>+2.8</p><p>(n=321)</p></td></tr><tr><td><p>Females</p></td><td><p>+0.4</p><p>(n=156)</p></td><td><p>+3.2</p><p>(n=162)</p></td></tr><tr><td><p>Males</p></td><td><p>-0.1</p><p>(n=145)</p></td><td><p>+2.4</p><p>(n=159)</p></td></tr></tbody></table><p>&nbsp;</p><p>Patients were randomized to flexibly dosed lurasidone 20 to 120 mg/day or placebo as adjunctive therapy with lithium or valproate.</p><p>The proportion of patients with prolactin elevations &ge;5x upper limit of normal (ULN) was 0.0% for lurasidone-treated patients and 0.0% for placebo-treated patients. The proportion of female patients with prolactin elevations &ge;5x ULN was 0% for lurasidone-treated patients and 0% for placebo-treated female patients. The proportion of male patients with prolactin elevations &ge;5x ULN was 0% and 0% for placebo-treated male patients.</p><p>In the uncontrolled, open-label, longer-term bipolar depression study, patients who were treated with lurasidone, as adjunctive therapy with either lithium or valproate, in the short-term and continued in the longer-term study, had a median change in prolactin of -2.9 ng/mL at week 24 (n=88).</p><p>&nbsp;</p><p><u>Pediatric Patients (10 to 17 years) </u></p><p>In the 6-week, placebo-controlled bipolar depression study with pediatric patients 10 to 17 years, the median change from baseline to endpoint in prolactin levels for lurasidone-treated patients was +1.10 ng/mL and was +0.50 ng/mL for placebo-treated patients. For lurasidone-treated patients, the median change from baseline to endpoint for males was +0.85 ng/mL and for females was +2.50 ng/mL. Median changes for prolactin are shown in Table 17.</p><p>&nbsp;</p><p><strong>Table 17: Median Change in Prolactin (ng/mL) from Baseline in the Bipolar Depression Study in Pediatric Patients (10 to 17 years)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>Lurasidone</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>Placebo</strong></p></td><td><p><strong>20 to 80 mg/day</strong></p></td></tr><tr><td><p>All Patients</p></td><td><p>+0.50</p><p>&nbsp;(n=157</p></td><td><p>+1.10</p><p>(n=165)</p></td></tr><tr><td><p>Females</p></td><td><p>+0.55</p><p>(n=78)</p></td><td><p>+2.50</p><p>&nbsp;(n=83)</p></td></tr><tr><td><p>Males</p></td><td><p>+0.50</p><p>(n=79)</p></td><td><p>+0.85</p><p>&nbsp;(n=82)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>The proportion of patients with prolactin elevations &ge;5x ULN was 0% for lurasidone-treated patients and 0.6% for placebo-treated patients. The proportion of female patients with prolactin elevations &ge;5x ULN was 0% for lurasidone -treated patients and 1.3% for placebo-treated female patients. No male patients in the placebo lurasidone-treatment groups had prolactin elevations &ge;5x ULN.</p><p><strong>&nbsp;</strong></p><p><strong>Leukopenia, Neutropenia and Agranulocytosis </strong></p><p>Leukopenia/neutropenia has been reported during treatment with antipsychotic agents. Agranulocytosis (including fatal cases) has been reported with other agents in the class.</p><p>Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC) and history of drug-induced leukopenia/neutropenia. Patients with a pre-existing low WBC or a history of drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and lurasidone should be discontinued at the first sign of decline in WBC, in the absence of other causative factors.</p><p>Patients with neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count &lt; 1000/mm<sup>3</sup>) should discontinue Laroza and have their WBC followed until recovery.</p><p>&nbsp;</p><p><strong>Orthostatic Hypotension and Syncope </strong></p><p>Lurasidone may cause orthostatic hypotension and syncope, perhaps due to its &alpha;1-adrenergic receptor antagonism. Associated adverse reactions can include dizziness, lightheadedness, tachycardia, and bradycardia. Generally, these risks are greatest at the beginning of treatment and during dose escalation. Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease, as well as patients who are antipsychotic-na&iuml;ve. In such patients, consider using a lower starting dose and slower titration, and monitor orthostatic vital signs.</p><p>&nbsp;</p><p>Orthostatic hypotension, as assessed by vital sign measurement, was defined by the following vital sign changes: &ge; 20 mm Hg decrease in systolic blood pressure and &ge;10 bpm increase in pulse from sitting to standing or supine to standing position.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;<strong><em>Schizophrenia </em></strong></p><p><u>Adults </u></p><p>The incidence of orthostatic hypotension and syncope reported as adverse events from short-term, placebo-controlled schizophrenia studies was (lurasidone incidence, placebo incidence): orthostatic hypotension [0.3% (5/1508), 0.1% (1/708)] and syncope [0.1% (2/1508), 0% (0/708)].</p><p>In short-term schizophrenia clinical studies, orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 0.8% with lurasidone 40 mg, 2.1% with lurasidone 80 mg, 1.7% with lurasidone 120 mg and 0.8% with lurasidone 160 mg compared to 0.7% with placebo.</p><p>&nbsp;</p><p><u>Adolescents </u></p><p>The incidence of orthostatic hypotension reported as adverse events from the short-term, placebo-controlled adolescent schizophrenia study was 0.5% (1/214) in lurasidone-treated patients and 0% (0/112) in placebo-treated patients. No syncope event was reported.</p><p>Orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 0% with lurasidone 40 mg and 2.9% with lurasidone 80 mg, compared to 1.8% with placebo.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Bipolar Depression </em></strong></p><p><u>Adults</u></p><p><em>Monotherapy</em></p><p>In the adult short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, there were no reported adverse events of orthostatic hypotension and syncope.</p><p>Orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 0.6% with lurasidone 20 to 60 mg and 0.6% with lurasidone 80 to 120 mg compared to 0% with placebo.</p><p>&nbsp;</p><p><em>Adjunctive Therapy with Lithium or Valproate </em></p><p>In the adult short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression therapy studies, there were no reported adverse events of orthostatic hypotension and syncope. Orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 1.1% with lurasidone 20 to 120 mg compared to 0.9% with placebo.</p><p>&nbsp;</p><p><u>Pediatric Patients (10 to 17 years) </u></p><p>In the 6-week, placebo-controlled bipolar depression study in pediatric patients 10 to 17 years, there were no reported adverse events of orthostatic hypotension or syncope.</p><p>Orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 1.1% with lurasidone 20 to 80 mg/day, compared to 0.6% with placebo.</p><p>&nbsp;</p><p><strong>Falls </strong></p><p>Laroza may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy.</p><p>&nbsp;</p><p><strong>Seizures </strong></p><p>As with other antipsychotic drugs, Laroza should be used cautiously in patients with a history of seizures or with conditions that lower the seizure threshold, e.g., Alzheimer&rsquo;s dementia. Conditions that lower the seizure threshold may be more prevalent in patients 65 years or older.</p><p><em>&nbsp;</em></p><p>&middot;&nbsp; &nbsp;<em>Schizophrenia </em></p><p>In adult short-term, placebo-controlled schizophrenia studies, seizures/convulsions occurred in 0.1% (2/1508) of patients treated with lurasidone compared to 0.1% (1/708) placebo-treated patients.</p><p>&nbsp;</p><p>&middot;&nbsp; Bipolar Depression</p><p><u>Monotherapy</u></p><p>In the adult and pediatric 6-week, flexible-dose, placebo-controlled monotherapy bipolar depression study, no patient experienced seizures/convulsions.</p><p>&nbsp;</p><p><u>Adjunctive Therapy with Lithium or Valproate </u></p><p>In the adult short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression studies, no patient experienced seizures/convulsions.</p><p>&nbsp;</p><p><strong>Potential for Cognitive and Motor Impairment </strong></p><p>Laroza, like other antipsychotics, has the potential to impair judgment, thinking or motor skills. Caution patients about operating hazardous machinery, including motor vehicles, until they are reasonably certain that therapy with Laroza does not affect them adversely.</p><p>In clinical studies with lurasidone, somnolence included: hypersomnia, hypersomnolence, sedation and somnolence.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;<strong><em>Schizophrenia </em></strong></p><p><u>Adults </u></p><p>In short-term, placebo-controlled schizophrenia studies, somnolence was reported by 17.0% (256/1508) of patients treated with lurasidone (15.5% lurasidone 20 mg, 15.6% lurasidone 40 mg, 15.2% lurasidone 80 mg, 26.5% lurasidone 120 mg and 8.3% lurasidone 160 mg/day) compared to 7.1% (50/708) of placebo patients.</p><p><u>&nbsp;</u></p><p><u>Adolescents </u></p><p>In the short-term, placebo-controlled adolescent schizophrenia study, somnolence was reported by 14.5% (31/214) of patients treated with lurasidone (15.5% lurasidone 40 mg and 13.5% lurasidone 80 mg/day) compared to 7.1% (8/112) of placebo patients.</p><p>&middot;&nbsp;&nbsp;<strong><em>Bipolar Depression </em></strong></p><p><u>Adults</u></p><p><em><u>Monotherapy </u></em></p><p>In the adult short-term, flexible-dosed, placebo-controlled monotherapy bipolar depression study, somnolence was reported by 7.3% (12/164) and 13.8% (23/167) with lurasidone 20 to 60 mg and 80 to120 mg, respectively compared to 6.5% (11/168) of placebo patients.</p><p>&nbsp;</p><p><em><u>Adjunctive Therapy with Lithium or Valproate </u></em></p><p>In the adult short-term, flexible-dosed, placebo-controlled adjunctive therapy bipolar depression studies, somnolence was reported by 11.4% (41/360) of patients treated with lurasidone 20-120 mg compared to 5.1% (17/334) of placebo patients.</p><p>&nbsp;</p><p><u>Pediatric Patients (10 to 17 years) </u></p><p>In the 6-week, placebo-controlled bipolar depression study in pediatric patients 10 to 17 years, somnolence was reported by 11.4% (20/175) of patients treated with lurasidone 20 to 80 mg/day compared to 5.8% (10/172) of placebo treated patients.</p><p>&nbsp;</p><p><strong>Body Temperature Dysregulation </strong></p><p>Disruption of the body&rsquo;s ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing Laroza for patients who will be experiencing conditions that may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration<em>. </em></p><p><strong>&nbsp;</strong></p><p><strong>Activation of Mania/Hypomania </strong></p><p>Antidepressant treatment can increase the risk of developing a manic or hypomanic episode, particularly in patients with bipolar disorder. Monitor patients for the emergence of such episodes.</p><p>In the adult bipolar depression monotherapy and adjunctive therapy (with lithium or valproate) studies, less than 1% of subjects in the lurasidone and placebo groups developed manic or hypomanic episodes.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Dysphagia </strong></p><p>Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer&rsquo;s dementia. Laroza and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.</p><p>&nbsp;</p><p><strong>Neurological Adverse Reactions in Patients with Parkinson&rsquo;s Disease or Dementia with Lewy Bodies </strong></p><p>Patients with Parkinson&rsquo;s Disease or Dementia with Lewy Bodies are reported to have an increased sensitivity to antipsychotic medication. Manifestations of this increased sensitivity include confusion, obtundation, postural instability with frequent falls, extrapyramidal symptoms, and clinical features consistent with the neuroleptic malignant syndrome.</p><p>&nbsp;</p><p><strong>Laroza contains lactose monohydrate</strong></p><p>Laroza contains lactose monohydrate. Each 120 mg film-coated tablet contains 190.80 mg lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Drugs Having Clinically Important Interactions with lurasidone </em></strong></p><p><strong>Table 18: Clinically Important Drug Interactions with lurasidone</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2"><p><strong>CYP3A4 Inhibitors </strong></p></td></tr><tr><td><p>Clinical Impact:</p></td><td><p>Concomitant use of lurasidone with strong CYP3A4 inhibitors increased the exposure of lurasidone compared to the use of lurasidone alone.</p></td></tr><tr><td><p>Intervention:</p></td><td><p>Lurasidone should not be used concomitantly with strong CYP3A4 inhibitors.</p></td></tr><tr><td><p>Examples:</p></td><td><p>Ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil</p></td></tr><tr><td colspan="2"><p><strong>Moderate CYP3A4 Inhibitors</strong></p></td></tr><tr><td><p>Clinical Impact:</p></td><td><p>Concomitant use of lurasidone with moderate CYP3A4 inhibitors increased the exposure of lurasidone compared to the use of lurasidone alone.</p></td></tr><tr><td><p>Intervention:</p></td><td><p>Lurasidone dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4.</p></td></tr><tr><td><p>Examples:</p></td><td><p>Diltiazem, atazanavir, erythromycin, fluconazole, verapamil</p></td></tr><tr><td colspan="2"><p><strong>Strong CYP3A4 Inducers</strong></p></td></tr><tr><td><p>Clinical Impact:</p></td><td><p>Concomitant use of lurasidone with strong CYP3A4 inducers decreased the exposure of lurasidone compared to the use of lurasidone alone.</p></td></tr><tr><td><p>Intervention:</p></td><td><p>Lurasidone should not be used concomitantly with strong CYP3A4 inhibitors</p></td></tr><tr><td><p>Examples:</p></td><td><p>Rifampin, avasimibe, St. John&rsquo;s wort, phenytoin, carbamazepine</p></td></tr><tr><td colspan="2"><p><strong>Moderate CYP3A4 Inducers</strong></p></td></tr><tr><td><p>Clinical Impact:</p></td><td><p>Concomitant use of lurasidone with moderate CYP3A4 inducers decreased the exposure of lurasidone compared to the use of lurasidone alone.</p></td></tr><tr><td><p>Intervention:</p></td><td><p>Lurasidone dose should be increased when used concomitantly with moderate inducers of CYP3A4.</p></td></tr><tr><td><p>Examples:</p></td><td><p>Bosentan, efavirenz, etravirine, modafinil, nafcillin</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><strong><em>Drugs Having No Clinically Important Interactions with lurasidone &nbsp;</em></strong></p><p>Based on pharmacokinetic studies, no dosage adjustment of lurasidone is required when administered concomitantly with lithium, valproate, or substrates of P-gp or CYP3A4.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Pregnancy </em></strong></p><p><u>Risk Summary </u></p><p>Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery.</p><p>There are no studies of lurasidone use in pregnant women. The limited available data are not sufficient to inform a drug-associated risk of birth defects or miscarriage. In animal reproduction studies, no teratogenic effects were seen in pregnant rats and rabbits given lurasidone during the period of organogenesis at doses approximately 1.5- and 6-times, the maximum recommended</p><p>human dose (MRHD) of 160 mg/day, respectively based on mg/m<sup>2 </sup>body surface area <em>(see Data)</em>.</p><p>The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</p><p>&nbsp;</p><p><u>Clinical Considerations </u></p><p><em>Fetal/Neonatal Adverse Reactions </em></p><p>Extrapyramidal and/or withdrawal symptoms, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder have been reported in neonates who were exposed to antipsychotic drugs during the third trimester of pregnancy. These symptoms have varied in severity. Some neonates recovered within hours or days without specific treatment; others required prolonged hospitalization. Monitor neonates for extrapyramidal and/or withdrawal symptoms and manage symptoms appropriately.</p><p>&nbsp;</p><p><u>Data </u></p><p><em>Animal Data </em></p><p>Pregnant rats were treated with oral lurasidone at doses of 3, 10, and 25 mg/kg/day during the period of organogenesis. These doses are 0.2, 0.6, and 1.5 times the MRHD of 160 mg/day based on mg/m<sup>2 </sup>body surface area. No teratogenic or embryo-fetal effects were observed up to 1.5 times the MHRD of 160 mg/day, based on mg/m<sup>2</sup>.</p><p>Pregnant rabbits were treated with oral lurasidone at doses of 2, 10, and 50 mg/kg/day during the period of organogenesis. These doses are 0.2, 1.2 and 6 times the MRHD of 160 mg/day based on mg/m<sup>2</sup>. No teratogenic or embryo-fetal effects were observed up to 6 times the MHRD of 160 mg/day based on mg/m<sup>2</sup>.</p><p>Pregnant rats were treated with oral lurasidone at doses of 0.4, 2, and 10 mg/kg/day during the periods of organogenesis and lactation. These doses are 0.02, 0.1 and 0.6 times the MRHD of 160 mg/day based on mg/m<sup>2</sup>. No pre- and postnatal developmental effects were observed up to 0.6 times the MRHD of 160 mg/day, based on mg/m<sup>2</sup>.</p><p>&nbsp;</p><p><strong><em>Lactation </em></strong></p><p><u>Risk Summary </u></p><p>Lactation studies have not been conducted to assess the presence of lurasidone in human milk, the effects on the breastfed infant, or the effects on milk production. Lurasidone is present in rat milk. The development and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for lurasidone and any potential adverse effects on the breastfed infant from lurasidone or from the underlying maternal condition.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lurasidone, like other antipsychotics, has the potential to impair judgment, thinking or motor skills. Caution patients about operating hazardous machinery, including motor vehicles, until they are reasonably certain that therapy with lurasidone does not affect them adversely.</p><p>In clinical studies with lurasidone, somnolence included: hypersomnia, hypersomnolence, sedation and somnolence.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following adverse reactions are discussed in more detail in other sections of the labeling:</p><p>&middot;&nbsp; Increased Mortality in Elderly Patients with Dementia-Related Psychosis</p><p>&middot;&nbsp;&nbsp;Suicidal Thoughts and Behaviors</p><p>&middot;&nbsp; Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-related Psychosis</p><p>&middot;&nbsp; Neuroleptic Malignant Syndrome</p><p>&middot; Tardive Dyskinesia</p><p>&middot;&nbsp; Metabolic Changes</p><p>&middot;&nbsp; Hyperprolactinemia</p><p>&middot;&nbsp; Leukopenia, Neutropenia, and Agranulocytosis</p><p>&middot;&nbsp;&nbsp;Orthostatic Hypotension and Syncope</p><p>&middot;&nbsp;&nbsp;&nbsp;Falls.&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;Seizures</p><p>&middot;&nbsp;&nbsp;&nbsp;Potential for Cognitive and Motor Impairment&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;Body Temperature Dysregulation</p><p>&middot;&nbsp;&nbsp;&nbsp;Activation of Mania/Hypomania</p><p>&middot;&nbsp; &nbsp;Dysphagia</p><p>&middot;&nbsp;&nbsp;&nbsp;Neurological Adverse Reactions in Patients with Parkinson&rsquo;s Disease or Dementia with Lewy Bodies</p><p>&nbsp;</p><p><strong><u>Clinical Trials Experience </u></strong></p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p><p>&nbsp;</p><p><u>Adults </u></p><p>The information below is derived from an integrated clinical study database for lurasidone consisting of 3799 adult patients exposed to one or more doses of lurasidone for the treatment of schizophrenia, and bipolar depression in placebo-controlled studies. This experience corresponds with a total experience of 1250.9 patient-years. A total of 1106 lurasidone -treated patients had at least 24 weeks and 371 lurasidone -treated patients had at least 52 weeks of exposure.</p><p>Adverse events during exposure to study treatment were obtained by general inquiry and voluntarily reported adverse experiences, as well as results from physical examinations, vital signs, ECGs, weights and laboratory investigations. Adverse experiences were recorded by clinical investigators using their own terminology. In order to provide a meaningful estimate of the proportion of individuals experiencing adverse events, events were grouped in standardized categories using MedDRA terminology.</p><p>&nbsp;</p><p><u>Schizophrenia </u></p><p>The following findings are based on the short-term, placebo-controlled premarketing adult studies for schizophrenia in which lurasidone was administered at daily doses ranging from 20 to 160 mg (n=1508).</p><p>&nbsp;</p><p><em>Commonly Observed Adverse Reactions: </em>The most common adverse reactions (incidence &ge; 5% and at least twice the rate of placebo) in patients treated with lurasidone were somnolence, akathisia, extrapyramidal symptoms, and nausea.</p><p>&nbsp;</p><p><em>Adverse Reactions Associated with Discontinuation of Treatment:<u> </u></em>A total of 9.5% (143/1508) lurasidone-treated patients and 9.3% (66/708) of placebo-treated patients discontinued due to adverse reactions. There were no adverse reactions associated with discontinuation in subjects treated with lurasidone that were at least 2% and at least twice the placebo rate.</p><p>&nbsp;</p><p><em>Adverse Reactions Occurring at an Incidence of 2% or More in </em>lurasidone <em>-Treated Patients: </em></p><p>Adverse reactions associated with the use of lurasidone (incidence of 2% or greater, rounded to the nearest percent and lurasidone incidence greater than placebo) that occurred during acute therapy (up to 6 weeks in patients with schizophrenia) are shown in Table 19.</p><p>&nbsp;</p><p><strong>Table 19: Adverse Reactions in 2% or More of lurasidone-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in Adult Short-term Schizophrenia Studies</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="8"><p><strong>Percentage of Patients Reporting Reaction</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td colspan="6"><p><strong>Lurasidone</strong></p></td></tr><tr><td><p><strong>Body System or Organ Class</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>(N=708) (%)</strong></p></td><td><p><strong>20 mg/day</strong></p><p><strong>(N=71)</strong></p><p><strong>(%)</strong></p></td><td><p><strong>40 mg/day</strong></p><p><strong>(N=487) (%)</strong></p></td><td><p><strong>80 mg/day (N=538) (%)</strong></p></td><td><p><strong>120 mg/day</strong></p><p><strong>(N=291) (%)</strong></p></td><td><p><strong>160 mg/day (N=121) (%)</strong></p></td><td><p><strong>All lurasidone</strong></p><p><strong>(N=1508) (%)</strong></p></td></tr><tr><td><p><strong>Gastrointestinal</strong></p><p><strong>Disorders</strong></p></td><td colspan="7"><p>&nbsp;</p></td></tr><tr><td><p>Nausea</p></td><td><p>5</p></td><td><p>11</p></td><td><p>10</p></td><td><p>9</p></td><td><p>13</p></td><td><p>7</p></td><td><p>10</p></td></tr><tr><td><p>Vomiting</p></td><td><p>6</p></td><td><p>7</p></td><td><p>6</p></td><td><p>9</p></td><td><p>9</p></td><td><p>7</p></td><td><p>8</p></td></tr><tr><td><p>Dyspepsia</p></td><td><p>5</p></td><td><p>11</p></td><td><p>6</p></td><td><p>5</p></td><td><p>8</p></td><td><p>6</p></td><td><p>6</p></td></tr><tr><td><p>Salivary Hypersecretion</p></td><td><p>&lt;1</p></td><td><p>1</p></td><td><p>1</p></td><td><p>2</p></td><td><p>4</p></td><td><p>2</p></td><td><p>2</p></td></tr><tr><td><p><strong>Musculoskeletal and Connective Tissue Disorders&nbsp; </strong></p></td><td colspan="7"><p>&nbsp;</p></td></tr><tr><td><p>Back Pain</p></td><td><p>2</p></td><td><p>0</p></td><td><p>4</p></td><td><p>3</p></td><td><p>4</p></td><td><p>0</p></td><td><p>3</p></td></tr><tr><td><p><strong>Nervous System Disorders </strong></p></td><td colspan="7"><p>&nbsp;</p></td></tr><tr><td><p>Somnolence*</p></td><td><p>7</p></td><td><p>15</p></td><td><p>16</p></td><td><p>15</p></td><td><p>26</p></td><td><p>8</p></td><td><p>17</p></td></tr><tr><td><p>Akathisia</p></td><td><p>3</p></td><td><p>6</p></td><td><p>11</p></td><td><p>12</p></td><td><p>22</p></td><td><p>7</p></td><td><p>13</p></td></tr><tr><td><p>Extrapyramidal Disorder**</p></td><td><p>6</p></td><td><p>6</p></td><td><p>11</p></td><td><p>12</p></td><td><p>22</p></td><td><p>13</p></td><td><p>14</p></td></tr><tr><td><p>Dizziness</p></td><td><p>2</p></td><td><p>6</p></td><td><p>4</p></td><td><p>4</p></td><td><p>5</p></td><td><p>6</p></td><td><p>4</p></td></tr><tr><td><p><strong>Psychiatric Disorders </strong></p></td><td colspan="7"><p>&nbsp;</p></td></tr><tr><td><p>Insomnia</p></td><td><p>8</p></td><td><p>8</p></td><td><p>10</p></td><td><p>11</p></td><td><p>9</p></td><td><p>7</p></td><td><p>10</p></td></tr><tr><td><p>Agitation</p></td><td><p>4</p></td><td><p>10</p></td><td><p>7</p></td><td><p>3</p></td><td><p>6</p></td><td><p>5</p></td><td><p>5</p></td></tr><tr><td><p>Anxiety</p></td><td><p>4</p></td><td><p>3</p></td><td><p>6</p></td><td><p>4</p></td><td><p>7</p></td><td><p>3</p></td><td><p>5</p></td></tr><tr><td><p>Restlessness</p></td><td><p>1</p></td><td><p>1</p></td><td><p>3</p></td><td><p>1</p></td><td><p>3</p></td><td><p>2</p></td><td><p>2</p></td></tr><tr><td colspan="8"><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Percentage of Patients Reporting Reaction</strong></p></td></tr></tbody></table><p>&nbsp;</p></td></tr><tr><td colspan="8"><p><strong>Lurasidone</strong></p></td></tr><tr><td><p><strong>Body System or Organ Class</strong></p></td><td><p><strong>Placebo (N=708) (%)</strong></p></td><td><p><strong>20 mg/day (N=71) (%)</strong></p></td><td><p><strong>40 mg/day (N=487) (%)</strong></p></td><td><p><strong>80 mg/day (N=538) (%)</strong></p></td><td><p><strong>120 mg/day (N=291) (%)</strong></p></td><td><p><strong>160 mg/day (N=121) (%)</strong></p></td><td><p><strong>All Lurasidone</strong></p><p><strong>(N=1508) (%)</strong></p></td></tr><tr><td><p><strong>Gastrointestinal Disorders</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td></tr><tr><td><p>Nausea</p></td><td><p>5</p></td><td><p>11</p></td><td><p>10</p></td><td><p>9</p></td><td><p>13</p></td><td><p>7</p></td><td><p>10</p></td></tr><tr><td><p>Vomiting</p></td><td><p>6</p></td><td><p>7</p></td><td><p>6</p></td><td><p>9</p></td><td><p>9</p></td><td><p>7</p></td><td><p>8</p></td></tr><tr><td><p>Dyspepsia</p></td><td><p>5</p></td><td><p>11</p></td><td><p>6</p></td><td><p>5</p></td><td><p>8</p></td><td><p>6</p></td><td><p>6</p></td></tr><tr><td><p>Salivary Hypersecretion</p></td><td><p>&lt;1</p></td><td><p>1</p></td><td><p>1</p></td><td><p>2</p></td><td><p>4</p></td><td><p>2</p></td><td><p>2</p></td></tr><tr><td colspan="8"><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Musculoskeletal and connective Tissue Disorders </strong></p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table><p>Note: Figures rounded to the nearest integer</p><p>* Somnolence includes adverse event terms: hypersomnia, hypersomnolence, sedation, and somnolence</p><p>** Extrapyramidal symptoms include adverse event terms: bradykinesia, cogwheel rigidity, drooling, dystonia, extrapyramidal disorder, hypokinesia, muscle rigidity, oculogyric crisis, oromandibular dystonia, parkinsonism, psychomotor retardation, tongue spasm, torticollis, tremor, and trismus</p><p>&nbsp;</p><p><em><u>Dose-Related Adverse Reactions in the Schizophrenia Studies </u></em></p><p>Akathisia and extrapyramidal symptoms were dose-related. The frequency of akathisia increased with dose up to 120 mg/day (5.6% for lurasidone 20 mg, 10.7% for lurasidone 40 mg, 12.3% for lurasidone 80 mg, and 22.0% for lurasidone 120 mg). Akathisia was reported by 7.4% (9/121) of patients receiving 160 mg/day. Akathisia occurred in 3.0% of subjects receiving placebo. The frequency of extrapyramidal symptoms increased with dose up to 120 mg/day (5.6% for lurasidone 20 mg, 11.5% for lurasidone 40 mg, 11.9% for lurasidone 80 mg, and 22.0% for lurasidone 120 mg).</p><p>&nbsp;</p><p><u>Bipolar Depression (Monotherapy) </u></p><p>The following findings are based on the adult short-term, placebo-controlled premarketing study for bipolar depression in which lurasidone was administered at daily doses ranging from 20 to 120 mg (n=331).</p><p>&nbsp;</p><p><em><u>Commonly Observed Adverse Reactions: </u></em>The most common adverse reactions (incidence &ge;5%, in either dose group, and at least twice the rate of placebo) in patients treated with lurasidone were akathisia, extrapyramidal symptoms, somnolence, nausea, vomiting, diarrhea, and anxiety.</p><p>&nbsp;</p><p><em><u>Adverse Reactions Associated with Discontinuation of Treatment: </u></em>A total of 6.0% (20/331) lurasidone -treated patients and 5.4% (9/168) of placebo-treated patients discontinued due to adverse reactions. There were no adverse reactions associated with discontinuation in subjects treated with lurasidone that were at least 2% and at least twice the placebo rate.</p><p>&nbsp;</p><p><em><u>Adverse Reactions Occurring at an Incidence of 2% or More in </u></em><u>lurasidone <em>-Treated Patients: </em></u></p><p>Adverse reactions associated with the use of lurasidone (incidence of 2% or greater, rounded to the nearest percent and lurasidone incidence greater than placebo) that occurred during acute therapy (up to 6 weeks in patients with bipolar depression) are shown in Table 20.</p><p>&nbsp;</p><p><strong>Table 20:</strong> <strong>Adverse Reactions in 2% or More of Lurasidone-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in the Adult Short-term Monotherapy Bipolar Depression Study</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5"><p><strong>Percentage of Patients Reporting Reaction</strong></p></td></tr><tr><td><p><strong>Body System or Organ Class</strong></p><p>Dictionary-derived Term</p></td><td><p><strong>Placebo</strong></p><p><strong>(N=168)</strong></p><p><strong>(%)</strong></p></td><td><p><strong>Lurasidone</strong></p><p><strong>20-60</strong></p><p><strong>mg/day</strong></p><p><strong>(N=164)</strong></p><p><strong>(%)</strong></p></td><td><p><strong>Lurasidone</strong></p><p><strong>80-120</strong></p><p><strong>mg/day</strong></p><p><strong>(N=167)</strong></p><p><strong>(%)</strong></p></td><td><p><strong>All Lurasidone</strong></p><p><strong>(N=331)</strong></p><p><strong>(%)</strong></p></td></tr><tr><td><p><strong>Gastrointestinal Disorders</strong></p></td><td colspan="4"><p>&nbsp;</p></td></tr><tr><td><p>Nausea</p></td><td><p>8</p></td><td><p>10</p></td><td><p>17</p></td><td><p>14</p></td></tr><tr><td><p>Dry Mouth</p></td><td><p>4</p></td><td><p>6</p></td><td><p>4</p></td><td><p>5</p></td></tr><tr><td><p>Vomiting</p></td><td><p>2</p></td><td><p>2</p></td><td><p>6</p></td><td><p>4</p></td></tr><tr><td><p>Diarrhea</p></td><td><p>2</p></td><td><p>5</p></td><td><p>3</p></td><td><p>4</p></td></tr><tr><td><p><strong>Infections and Infestations</strong></p></td><td colspan="4"><p>&nbsp;</p></td></tr><tr><td><p>Nasopharyngitis</p></td><td><p>1</p></td><td><p>4</p></td><td><p>4</p></td><td><p>4</p></td></tr><tr><td><p>Influenza</p></td><td><p>1</p></td><td><p>&lt;1</p></td><td><p>2</p></td><td><p>2</p></td></tr><tr><td><p>Urinary Tract Infection</p></td><td><p>&lt;1</p></td><td><p>2</p></td><td><p>1</p></td><td><p>2</p></td></tr><tr><td><p><strong>Musculoskeletal and Connective Tissue Disorder </strong></p></td><td colspan="4"><p>&nbsp;</p></td></tr><tr><td><p>Back Pain</p></td><td><p>&lt;1</p></td><td><p>3</p></td><td><p>&lt;1</p></td><td><p>2</p></td></tr><tr><td><p><strong>Nervous System Disorders </strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Extrapyramidal Symptoms*</p></td><td><p>2</p></td><td><p>5</p></td><td><p>9</p></td><td><p>7</p></td></tr><tr><td><p>Akathisia</p></td><td><p>2</p></td><td><p>8</p></td><td><p>11</p></td><td><p>9</p></td></tr><tr><td><p>Somnolence**</p></td><td><p>7</p></td><td><p>7</p></td><td><p>14</p></td><td><p>11</p></td></tr><tr><td><p><strong>Psychiatric Disorders</strong></p></td><td colspan="4"><p>&nbsp;</p></td></tr><tr><td><p>Anxiety</p></td><td><p>1</p></td><td><p>4</p></td><td><p>5</p></td><td><p>4</p></td></tr></tbody></table><p>Note: Figures rounded to the nearest integer</p><p>*Extrapyramidal symptoms include adverse event terms: bradykinesia, cogwheel rigidity, drooling, dystonia, extrapyramidal disorder, glabellar reflex abnormal, hypokinesia, muscle rigidity, oculogyric crisis, oromandibular dystonia, parkinsonism, psychomotor retardation, tongue spasm, torticollis, tremor, and trismus</p><p>&nbsp;** Somnolence includes adverse event terms: hypersomnia, hypersomnolence, sedation, and somnolence</p><p>&nbsp;</p><p><em><u>Dose-Related Adverse Reactions in the Monotherapy Study:</u></em></p><p>In the adult short-term, placebo-controlled study (involving lower and higher lurasidone dose ranges)<em> </em>the adverse reactions that occurred with a greater than 5% incidence in the patients treated with lurasidone in any dose group and greater than placebo in both groups were nausea (10.4%, 17.4%), somnolence (7.3%, 13.8%), akathisia (7.9%, 10.8%), and extrapyramidal symptoms (4.9%, 9.0%) for lurasidone 20 to 60 mg/day and lurasidone 80 to 120 mg/day, respectively.</p><p>&nbsp;</p><p><u>Bipolar Depression (Adjunctive Therapy with Lithium or Valproate) </u></p><p>The following findings are based on two adult short-term, placebo-controlled premarketing studies for bipolar depression in which lurasidone was administered at daily doses ranging from 20 to 120 mg as adjunctive therapy with lithium or valproate (n=360).</p><p>&nbsp;</p><p><em><u>Commonly Observed Adverse Reactions: </u></em>The most common adverse reactions (incidence &ge;5% and at least twice the rate of placebo) in subjects treated with lurasidone were akathisia and somnolence.</p><p>&nbsp;</p><p><em><u>Adverse Reactions Associated with Discontinuation of Treatment: </u></em>A total of 5.8% (21/360) lurasidone-treated patients and 4.8% (16/334) of placebo-treated patients discontinued due to adverse reactions. There were no adverse reactions associated with discontinuation in subjects treated with lurasidone that were at least 2% and at least twice the placebo rate.</p><p>&nbsp;</p><p><em><u>Adverse Reactions Occurring at an Incidence of 2% or More in lurasidone -Treated Patients: </u></em></p><p>Adverse reactions associated with the use of lurasidone (incidence of 2% or greater, rounded to the nearest percent and lurasidone incidence greater than placebo) that occurred during acute therapy (up to 6 weeks in patients with bipolar depression) are shown in Table 21.</p><p>&nbsp;</p><p><strong>Table 21:</strong> <strong>Adverse Reactions in 2% or More of lurasidone-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in the Adult Short-term Adjunctive Therapy Bipolar Depression Studies</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td colspan="2"><p><strong>Percentage of Patients Reporting Reaction</strong></p></td></tr><tr><td><p><strong>Body System or Organ Class</strong></p><p>Dictionary-derived Term</p></td><td><p><strong>Placebo</strong></p><p><strong>(N=334)</strong></p><p><strong>(%)</strong></p></td><td><p><strong>Lurasidone</strong></p><p><strong>20 to 120 mg/day</strong></p><p><strong>(N=360)</strong></p><p><strong>(%)</strong></p></td></tr><tr><td><p><strong>Gastrointestinal Disorders</strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Nausea</p></td><td><p>10</p></td><td><p>14</p></td></tr><tr><td><p>Vomiting</p></td><td><p>1</p></td><td><p>4</p></td></tr><tr><td><p><strong>General Disorders </strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Fatigue</p></td><td><p>1</p></td><td><p>3</p></td></tr><tr><td><p><strong>Infections and Infestations </strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Nasopharyngitis</p></td><td><p>2</p></td><td><p>4</p></td></tr><tr><td><p><strong>Investigations </strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Weight Increased</p></td><td><p>&lt;1</p></td><td><p>3</p></td></tr><tr><td><p><strong>Metabolism and Nutrition Disorders </strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Increased Appetite</p></td><td><p>1</p></td><td><p>3</p></td></tr><tr><td><p><strong>Nervous System Disorders </strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Extrapyramidal Symptoms*</p></td><td><p>9</p></td><td><p>14</p></td></tr><tr><td><p>Somnolence**</p></td><td><p>5</p></td><td><p>11</p></td></tr><tr><td><p>Akathisia</p></td><td><p>5</p></td><td><p>11</p></td></tr><tr><td><p><strong>Psychiatric Disorders </strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Restlessness</p></td><td><p>&lt;1</p></td><td><p>4</p></td></tr></tbody></table><p>Note: Figures rounded to the nearest integer</p><p>*Extrapyramidal symptoms include adverse event terms: bradykinesia, cogwheel rigidity, drooling, dystonia, extrapyramidal disorder, glabellar reflex abnormal, hypokinesia, muscle rigidity, oculogyric crisis, oromandibular dystonia, parkinsonism, psychomotor retardation, tongue spasm, torticollis, tremor, and trismus</p><p>** Somnolence includes adverse event terms: hypersomnia, hypersomnolence, sedation, and somnolence</p><p><strong><em>&nbsp;</em></strong></p><p><strong><u>Adolescents </u></strong></p><p><em>Schizophrenia</em></p><p>The following findings are based on the short-term, placebo-controlled adolescent study for schizophrenia in which lurasidone was administered at daily doses ranging from 40 (N=110) to 80 mg (N=104).</p><p>&nbsp;</p><p><em><u>Commonly Observed Adverse Reactions:</u></em></p><p>The most common adverse reactions (incidence &ge;5% and at least twice the rate of placebo) in adolescent patients (13 to 17 years) treated with lurasidone were somnolence, nausea, akathisia, extrapyramidal symptoms (non-akathisia, 40mg only), vomiting, and rhinorrhea/rhinitis (80mg only).</p><p>&nbsp;</p><p><em><u>Adverse Reactions Associated with Discontinuation of Treatment: </u></em></p><p>The incidence of discontinuation due to adverse reactions between lurasidone-and placebo-treated adolescent patients (13 to 17 years) was 4% and 8%, respectively.</p><p>&nbsp;</p><p><em><u>Adverse Reactions Occurring at an Incidence of 2% or More in lurasidone-Treated Patients:</u></em></p><p>Adverse reactions associated with the use of lurasidone (incidence of 2% or greater, rounded to the nearest percent and lurasidone incidence greater than placebo) that occurred during acute therapy (up to 6-weeks in adolescent patients with schizophrenia) are shown in Table 22.</p><p><strong>&nbsp;</strong></p><p><strong>Table 22: Adverse Reactions in 2% or More of Lurasidone-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in the Adolescent Short-term Schizophrenia Study</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="7"><p><strong>Percentage of Patients Reporting Reaction</strong></p></td></tr><tr><td><p><strong>Body System or Organ Class </strong></p><p><strong>Dictionary-derived Term </strong></p></td><td><p><strong>Placebo</strong></p><p><strong>(N=112)</strong></p></td><td colspan="2"><p><strong>Lurasidone</strong></p><p><strong>40 mg/day</strong></p><p><strong>(N=110)</strong></p></td><td><p><strong>Lurasidone</strong></p><p><strong>80 mg/day</strong></p><p><strong>(N=104)</strong></p></td><td colspan="2"><p><strong>All</strong></p><p><strong>Lurasidone</strong></p><p><strong>(N=214)</strong></p></td></tr><tr><td><p><strong>Gastrointestinal Disorders </strong></p></td><td colspan="6"><p>&nbsp;</p></td></tr><tr><td><p>Nausea</p></td><td colspan="2"><p>3</p></td><td><p>13</p></td><td colspan="2"><p>14</p></td><td><p>14</p></td></tr><tr><td><p>Vomiting</p></td><td colspan="2"><p>2</p></td><td><p>8</p></td><td colspan="2"><p>6</p></td><td><p>8</p></td></tr><tr><td><p>Diarrhea</p></td><td colspan="2"><p>1</p></td><td><p>3</p></td><td colspan="2"><p>5</p></td><td><p>4</p></td></tr><tr><td><p>Dry Mouth</p></td><td colspan="2"><p>0</p></td><td><p>2</p></td><td colspan="2"><p>3</p></td><td><p>2</p></td></tr><tr><td><p><strong>Infections and Infestations </strong></p></td><td colspan="6"><p>&nbsp;</p></td></tr><tr><td><p>Viral Infection**</p></td><td colspan="2"><p>6</p></td><td><p>11</p></td><td colspan="2"><p>10</p></td><td><p>10</p></td></tr><tr><td><p>Rhinitis***</p></td><td colspan="2"><p>2</p></td><td><p>&lt;1</p></td><td colspan="2"><p>8</p></td><td><p>4</p></td></tr><tr><td><p>Oropharyngeal pain</p></td><td colspan="2"><p>0</p></td><td><p>&lt;1</p></td><td colspan="2"><p>3</p></td><td><p>2</p></td></tr><tr><td><p>Tachycardia</p></td><td colspan="2"><p>0</p></td><td><p>0</p></td><td colspan="2"><p>3</p></td><td><p>1</p></td></tr><tr><td><p><strong>Nervous System Disorders </strong></p></td><td colspan="6"><p>&nbsp;</p></td></tr><tr><td><p>Somnolence*</p></td><td colspan="2"><p>7</p></td><td><p>15</p></td><td colspan="2"><p>13</p></td><td><p>15</p></td></tr><tr><td><p>Akathisia</p></td><td colspan="2"><p>2</p></td><td><p>9</p></td><td colspan="2"><p>9</p></td><td><p>9</p></td></tr><tr><td><p>Dizziness</p></td><td colspan="2"><p>1</p></td><td><p>5</p></td><td colspan="2"><p>5</p></td><td><p>5</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>Note: Figures rounded to the nearest integer</p><p>* Somnolence includes adverse event terms: hypersomnia, sedation, and somnolence</p><p>** Viral Infection includes adverse event terms: nasopharyngitis, influenza, viral infection, upper respiratory tract infection</p><p>&nbsp;*** Rhinitis incudes adverse event terms: rhinitis, allergic rhinitis, rhinorrhea, and nasal congestion</p><p>&nbsp;</p><p><strong><u>Pediatric Patients (10 to 17 years)</u></strong></p><p><em>Bipolar Depression </em></p><p>The following findings are based on the 6-week , placebo-controlled study for bipolar depression in pediatric patients 10 to 17 years in which lurasidone was administered at daily doses ranging from 20 to 80 mg (N=175).</p><p>&nbsp;</p><p><em><u>Commonly Observed Adverse Reactions: </u></em>The most common adverse reactions (incidence &ge;5%, and at least twice the rate of placebo) in pediatric patients (10 to 17 years) treated with lurasidone were nausea, weight increase, and insomnia.</p><p>&nbsp;</p><p><em><u>Adverse Reactions Associated with Discontinuation of Treatment: </u></em>The incidence of discontinuation due to adverse reactions between lurasidone- and placebo-treated pediatric patients 10 to 17 years was 2% and 2%, respectively.</p><p>&nbsp;</p><p><em><u>Adverse Reactions Occurring at an Incidence of 2% or More in Lurasidone -Treated Patients: </u></em></p><p>Adverse reactions associated with the use of lurasidone (incidence of 2% or greater, rounded to the nearest percent and lurasidone incidence greater than placebo) that occurred during acute therapy (up to 6 weeks in pediatric patients with bipolar depression) are shown in Table 23.</p><p>&nbsp;</p><p><strong>Table 23: Adverse Reactions in 2% or More of lurasidone -Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in the 6&shy;Week Bipolar Depression Study in Pediatric Patients (10 to 17 years)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td colspan="2"><p><strong>Percentage of Patients Reporting Reaction</strong></p></td></tr><tr><td><p><strong>Body System or Organ Class</strong></p><p><strong>Dictionary-derived Term</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>(N=172)</strong></p><p><strong>(%)</strong></p></td><td><p><strong>Lurasidone</strong></p><p><strong>20 to 80 mg/day</strong></p><p><strong>(N=175)</strong></p><p><strong>(%)</strong></p></td></tr><tr><td><p><strong>Gastrointestinal Disorders</strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Nausea</p></td><td><p>6</p></td><td><p>16</p></td></tr><tr><td><p>Vomiting</p></td><td><p>4</p></td><td><p>6</p></td></tr><tr><td><p>Abdominal Pain Upper</p></td><td><p>2</p></td><td><p>3</p></td></tr><tr><td><p>Diarrhea</p></td><td><p>2</p></td><td><p>3</p></td></tr><tr><td><p>Abdominal Pain</p></td><td><p>1</p></td><td><p>3</p></td></tr><tr><td><p><strong>General Disorders And Administration Site Conditions</strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Fatigue</p></td><td><p>2</p></td><td><p>3</p></td></tr><tr><td><p><strong>Investigations</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Weight Increased</p></td><td><p>2</p></td><td><p>7</p></td></tr><tr><td><p><strong>Metabolism and Nutrition Disorders</strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Decreased Appetite</p></td><td><p>2</p></td><td><p>4</p></td></tr><tr><td><p><strong>Nervous System Disorders </strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Somnolence*</p></td><td><p>6</p></td><td><p>11</p></td></tr><tr><td><p>Extrapyramidal Symptoms**</p></td><td><p>5</p></td><td><p>6</p></td></tr><tr><td><p>Dizziness</p></td><td><p>5</p></td><td><p>6</p></td></tr><tr><td><p><strong>Psychiatric Disorders </strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Insomnia</p></td><td><p>2</p></td><td><p>5</p></td></tr><tr><td><p>Abnormal Dreams</p></td><td><p>2</p></td><td><p>2</p></td></tr><tr><td><p><strong>Respiratory, Thoracic and Mediastinal Disorders </strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>Oropharyngeal Pain</p></td><td><p>2</p></td><td><p>2</p></td></tr></tbody></table><p>Note: Figures rounded to the nearest integer</p><p>*Somnolence includes adverse event terms: hypersomnia, hypersomnolence, sedation, and somnolence</p><p>**EPS includes adverse event terms: akathisia, cogwheel rigidity, dyskinesia, dystonia, hyperkinesia, joint stiffness, muscle rigidity, muscle spasms, musculoskeletal stiffness, oculogyric crisis, parkinsonism, tardive dyskinesia, and tremor</p><p>&nbsp;</p><p><em><u>Extrapyramidal Symptoms</u></em></p><p>&middot;&nbsp;<em>Schizophrenia</em></p><p><em>&nbsp;Adults </em></p><p>In the short-term, placebo-controlled schizophrenia studies, for lurasidone-treated patients, the incidence of reported events related to extrapyramidal symptoms (EPS), excluding akathisia and restlessness, was 13.5% and 5.8% for placebo-treated patients. The incidence of akathisia for lurasidone-treated patients was 12.9% and 3.0% for placebo-treated patients. Incidence of EPS by dose is provided in Table 24.</p><p>&nbsp;</p><p>&nbsp;<strong>Table 24: Incidence of EPS Compared to Placebo in Adult Schizophrenia Studies </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="7"><p><strong>Lurasidone</strong></p></td></tr><tr><td><p><strong>Adverse Event Term </strong></p></td><td><p><strong>Placebo</strong></p><p><strong>(N=708)</strong></p><p><strong>(%)</strong></p></td><td><p><strong>20 mg/day (N=71)</strong></p><p><strong>(%)</strong></p></td><td><p><strong>40 mg/day (N=487)</strong></p><p><strong>(%)</strong></p></td><td><p><strong>80 mg/day</strong></p><p><strong>(N=538) (%)</strong></p></td><td><p><strong>120 mg/day</strong></p><p><strong>(N=291)</strong></p><p><strong>(%)</strong></p></td><td><p><strong>160 mg/day (N=121) (%)</strong></p></td></tr><tr><td><p><strong>All EPS events </strong></p></td><td><p><strong>9 </strong></p></td><td><p><strong>10 </strong></p></td><td><p><strong>21 </strong></p></td><td><p><strong>23 </strong></p></td><td><p><strong>39 </strong></p></td><td><p><strong>20 </strong></p></td></tr><tr><td><p><strong>All EPS events, </strong></p><p><strong>excluding </strong></p><p><strong>Akathisia/Restlessness </strong></p></td><td><p><strong>6 </strong></p></td><td><p><strong>6 </strong></p></td><td><p><strong>11 </strong></p></td><td><p><strong>12 </strong></p></td><td><p><strong>22 </strong></p></td><td><p><strong>13</strong></p></td></tr><tr><td><p>Akathisia</p></td><td><p>3</p></td><td><p>6</p></td><td><p>11</p></td><td><p>12</p></td><td><p>22</p></td><td><p>7</p></td></tr><tr><td><p>Dystonia*</p></td><td><p>&lt;1</p></td><td><p>0</p></td><td><p>4</p></td><td><p>5</p></td><td><p>7</p></td><td><p>2</p></td></tr><tr><td><p>Parkinsonism**</p></td><td><p>5</p></td><td><p>6</p></td><td><p>9</p></td><td><p>8</p></td><td><p>17</p></td><td><p>11</p></td></tr><tr><td><p>Restlessness</p></td><td><p>1</p></td><td><p>1</p></td><td><p>3</p></td><td><p>1</p></td><td><p>3</p></td><td><p>2</p></td></tr></tbody></table><p>Note: Figures rounded to the nearest integer</p><p>* Dystonia includes adverse event terms: dystonia, oculogyric crisis, oromandibular dystonia, tongue spasm, torticollis, and trismus</p><p>** Parkinsonism includes adverse event terms: bradykinesia, cogwheel rigidity, drooling, extrapyramidal disorder, hypokinesia, muscle rigidity, parkinsonism, psychomotor retardation, and tremor</p><p><em>&nbsp;</em></p><p><em>Adolescents </em></p><p>In the short-term, placebo-controlled, study of schizophrenia in adolescents, the incidence of EPS, excluding events related to akathisia, for lurasidone-treated patients was higher in the 40 mg (10%) and the 80 mg (7.7%) treatment groups vs. placebo (3.6%); and the incidence of akathisia-related events for lurasidone-treated patients was 8.9% vs. 1.8% for placebo-treated patients. Incidence of EPS by dose is provided in Table 25.</p><p>&nbsp;</p><p><strong>Table 25: Incidence of EPS Compared to Placebo in the Adolescent Schizophrenia Study</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td colspan="2"><p><strong>Lurasidone</strong></p></td></tr><tr><td><p><strong>Adverse Event Term</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>(N=112)</strong></p><p><strong>(%)</strong></p></td><td><p><strong>40 mg/day</strong></p><p><strong>(N=110)</strong></p><p><strong>(%)</strong></p></td><td><p><strong>80 mg/day</strong></p><p><strong>(N=104)</strong></p><p><strong>(%)</strong></p></td></tr><tr><td><p><strong>All EPS events</strong></p></td><td><p><strong>5</strong></p></td><td><p><strong>14</strong></p></td><td><p><strong>14</strong></p></td></tr><tr><td><p><strong>All EPS events, excluding Akathisia/Restlessness</strong></p></td><td><p><strong>4</strong></p></td><td><p><strong>7</strong></p></td><td><p><strong>7</strong></p></td></tr><tr><td><p>Akathisia</p></td><td><p>2</p></td><td><p>9</p></td><td><p>9</p></td></tr><tr><td><p>Parkinsonism**</p></td><td><p>&lt;1</p></td><td><p>4</p></td><td><p>0</p></td></tr><tr><td><p>Dyskinesia</p></td><td><p>&lt;1</p></td><td><p>&lt;1</p></td><td><p>1</p></td></tr><tr><td><p>Dystonia*</p></td><td><p>&nbsp;0</p></td><td><p>&lt;1</p></td><td><p>1</p></td></tr></tbody></table><p>Note: Figures rounded to the nearest integer</p><p>* Dystonia includes adverse event terms: dystonia, trismus, oculogyric crisis, oromandibular dystonia, tongue spasm, and torticollis</p><p>** Parkinsonism includes adverse event terms: bradykinesia, drooling, extrapyramidal disorder, glabellar reflex abnormal, hypokinesia, parkinsonism, and psychomotor retardation</p><p>&nbsp;</p><p>&middot;&nbsp;<em>Bipolar Depression </em></p><p><u>Adults</u></p><p><em>Monotherapy </em></p><p>In the adult short-term, placebo-controlled monotherapy bipolar depression study, for lurasidone-treated patients, the incidence of reported events related to EPS, excluding akathisia and restlessness was 6.9% and 2.4% for placebo-treated patients. The incidence of akathisia for lurasidone-treated patients was 9.4% and 2.4% for placebo-treated patients. Incidence of EPS by dose groups is provided in Table 26.</p><p>&nbsp;</p><p><strong>Table 26: Incidence of EPS Compared to Placebo in the Adult Monotherapy Bipolar Depression Study</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>&nbsp;</strong></p></td><td colspan="2"><p><strong>Lurasidone</strong></p></td></tr><tr><td><p><strong>Adverse Event Term</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>(N=168)</strong></p><p><strong>(%)</strong></p></td><td><p><strong>20 to 60 mg/day</strong></p><p><strong>(N=164)</strong></p><p><strong>(%)</strong></p></td><td><p><strong>80 to 120 mg/day</strong></p><p><strong>(N=167)</strong></p><p><strong>(%)</strong></p></td></tr><tr><td><p><strong>All EPS events</strong></p></td><td><p><strong>5</strong></p></td><td><p><strong>12</strong></p></td><td><p><strong>20</strong></p></td></tr><tr><td><p><strong>All EPS events excluding Akathisia/Restlessness</strong></p></td><td><p><strong>2</strong></p></td><td><p><strong>5</strong></p></td><td><p><strong>9</strong></p></td></tr><tr><td><p>Akathisia</p></td><td><p>2</p></td><td><p>8</p></td><td><p>11</p></td></tr><tr><td><p>Dystonia*</p></td><td><p>0</p></td><td><p>0</p></td><td><p>2</p></td></tr><tr><td><p>Parkinsonism**</p></td><td><p>2</p></td><td><p>5</p></td><td><p>8</p></td></tr><tr><td><p>Restlessness</p></td><td><p>&lt;1</p></td><td><p>0</p></td><td><p>3</p></td></tr></tbody></table><p>Note: Figures rounded to the nearest integer</p><p>* Dystonia includes adverse event terms: dystonia, oculogyric crisis, oromandibular dystonia, tongue spasm, torticollis, and trismus</p><p>** Parkinsonism includes adverse event terms: bradykinesia, cogwheel rigidity, drooling, extrapyramidal disorder, glabellar reflex abnormal, hypokinesia, muscle rigidity, parkinsonism, psychomotor retardation, and tremor</p><p>&nbsp;</p><p><em>Adjunctive Therapy with Lithium or Valproate </em></p><p>In the adult short-term, placebo-controlled adjunctive therapy bipolar depression studies, for lurasidone-treated patients, the incidence of EPS, excluding akathisia and restlessness, was 13.9% and 8.7% for placebo. The incidence of akathisia for lurasidone-treated patients was 10.8% and 4.8% for placebo-treated patients. Incidence of EPS is provided in Table 27.</p><p>&nbsp;</p><p><strong>Table 27: Incidence of EPS Compared to Placebo in the Adult Adjunctive Therapy Bipolar Depression Studies</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Adverse Event Term</strong></p></td><td><p><strong>&nbsp;</strong><strong>Placebo</strong></p><p><strong>&nbsp;(N=334)</strong></p><p><strong>(%)</strong></p></td><td><p><strong>Lurasidone</strong></p><p><strong>20 to 120 mg/day</strong></p><p><strong>(N=360)</strong></p><p><strong>(%)</strong></p></td></tr><tr><td><p><strong>All EPS events</strong></p></td><td><p><strong>13</strong></p></td><td><p><strong>24</strong></p></td></tr><tr><td><p><strong>All EPS events excluding Akathisia/Restlessness</strong></p></td><td><p><strong>9</strong></p></td><td><p><strong>14</strong></p></td></tr><tr><td><p>Akathisia</p></td><td><p>5</p></td><td><p>11</p></td></tr><tr><td><p>Dystonia*</p></td><td><p>&lt;1</p></td><td><p>1</p></td></tr><tr><td><p>Parkinsonism**</p></td><td><p>8</p></td><td><p>13</p></td></tr><tr><td><p>Restlessness</p></td><td><p>&lt;1</p></td><td><p>4</p></td></tr></tbody></table><p>Note: Figures rounded to the nearest integer</p><p>* Dystonia includes adverse event terms: dystonia, oculogyric crisis, oromandibular dystonia, tongue spasm, torticollis, and trismus</p><p>** Parkinsonism includes adverse event terms: bradykinesia, cogwheel rigidity, drooling, extrapyramidal disorder, glabellar reflex abnormal, hypokinesia, muscle rigidity, parkinsonism, psychomotor retardation, and tremor</p><p><strong>&nbsp;</strong></p><p>In the short-term, placebo-controlled schizophrenia and bipolar depression studies, data was objectively collected on the Simpson Angus Rating Scale (SAS) for extrapyramidal symptoms (EPS), the Barnes Akathisia Scale (BAS) for akathisia and the Abnormal Involuntary Movement Scale (AIMS) for dyskinesias.</p><p>&nbsp;</p><p><u>Pediatric Patients (10 to 17 years) </u></p><p>In the 6-week, placebo-controlled study of bipolar depression in pediatric patients 10 to 17 years, the incidence of EPS, excluding events related to akathisia, for lurasidone-treated patients was similar in the lurasidone 20 to 80 mg/day (3.4%) treatment group vs. placebo (3.5%); and the incidence of akathisia-related events for lurasidone-treated patients was 2.9% vs. 3.5% for placebo-treated patients. Incidence of EPS by dose is provided in Table 28.</p><p>&nbsp;</p><p><strong>Table 28: Incidence of EPS Compared to Placebo in the Bipolar Depression Study in Pediatric Patients (10 to 17 years)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Adverse Event Term</strong></p></td><td><p><strong>&nbsp;</strong><strong>Placebo</strong></p><p><strong>&nbsp;(N=172)</strong></p><p><strong>(%)</strong></p></td><td><p><strong>Lurasidone</strong></p><p><strong>20 to 80 mg/day</strong></p><p><strong>(N=175)</strong></p><p><strong>(%)</strong></p></td></tr><tr><td><p><strong>All EPS events</strong></p></td><td><p><strong>5 </strong></p></td><td><p><strong>6 </strong></p></td></tr><tr><td><p><strong>All EPS events excluding Akathisia/Restlessness</strong></p></td><td><p><strong>4 </strong></p></td><td><p><strong>3 </strong></p></td></tr><tr><td><p>Akathisia</p></td><td><p>4</p></td><td><p>3</p></td></tr><tr><td><p>Parkinsonism**</p></td><td><p>&lt;1</p></td><td><p>&lt;1</p></td></tr><tr><td><p>Dystonia***</p></td><td><p>1</p></td><td><p>&lt;1</p></td></tr><tr><td><p>Salivary hypersecretion</p></td><td><p>&lt;1</p></td><td><p>&lt;1</p></td></tr><tr><td><p>Psychomotor hyperactivity</p></td><td><p>0</p></td><td><p>&lt;1</p></td></tr><tr><td><p>Tardive Dyskinesia</p></td><td><p>&lt;1</p></td><td><p>0</p></td></tr></tbody></table><p>Note: Figures rounded to the nearest integer</p><p>* EPS include adverse event terms: akathisia, cogwheel rigidity, dyskinesia, dystonia, hyperkinesia, joint stiffness, muscle rigidity, muscle spasms, musculoskeletal stiffness, oculogyric crisis, parkinsonism, tardive dyskinesia, and tremor ** Parkinsonism includes adverse event terms: bradykinesia, drooling, extrapyramidal disorder, glabellar reflex abnormal, hypokinesia, parkinsonism, and psychomotor retardation</p><p>&nbsp;***Dystonia includes adverse event terms: dystonia, oculogyric crisis, oromandibular dystonia, tongue spasm, torticollis, and trismus</p><p>&nbsp;</p><p>&middot;&nbsp;<em>Schizophrenia </em></p><p><em><u>Adults </u></em></p><p>The mean change from baseline for lurasidone-treated patients for the SAS, BAS and AIMS was comparable to placebo-treated patients, with the exception of the Barnes Akathisia Scale global score (lurasidone, 0.1; placebo, 0.0). The percentage of patients who shifted from normal to abnormal was greater in lurasidone-treated patients and placebo for the BAS (lurasidone, 14.4%; placebo, 7.1%), the SAS (lurasidone, 5.0%; placebo, 2.3%) and the AIMS (lurasidone, 7.4%; placebo, 5.8%).</p><p>&nbsp;</p><p><em><u>Adolescents </u></em></p><p>The mean change from baseline for lurasidone- treated patients with adolescent schizophrenia for the SAS, BAS and AIMS was comparable to placebo-treated patients. The percentage of patients who shifted from normal to abnormal was greater in lurasidone-treated patients and placebo for the BAS (lurasidone, 7.0%; placebo, 1.8%), the SAS (lurasidone, 8.3%; placebo, 2.7%) and the AIMS (lurasidone, 2.8%; placebo, 0.9%).</p><p>&nbsp;</p><p>&middot;&nbsp;<strong><em>Bipolar Depression </em></strong></p><p><u>Adults</u></p><p><em>Monotherapy </em></p><p>The mean change from baseline for lurasidone-treated adult patients for the SAS, BAS and AIMS was comparable to placebo-treated patients. The percentage of patients who shifted from normal to abnormal was greater in lurasidone-treated patients and placebo for the BAS (lurasidone, 8.4%; placebo, 5.6%), the SAS (lurasidone, 3.7%; placebo, 1.9%) and the AIMS (lurasidone, 3.4%; placebo, 1.2%).</p><p><em>&nbsp;</em></p><p><em>Adjunctive Therapy with Lithium or Valproate </em></p><p>The mean change from baseline for lurasidone-treated adult patients for the SAS, BAS and AIMS was comparable to placebo-treated patients. The percentage of patients who shifted from normal to abnormal was greater in lurasidone-treated patients and placebo for the BAS (lurasidone, 8.7%; placebo, 2.1%), the SAS (lurasidone, 2.8%; placebo, 2.1%) and the AIMS (lurasidone, 2.8%; placebo, 0.6%).</p><p>&nbsp;</p><p><u>Pediatric Patients (10 to 17 years) </u></p><p>The mean change from baseline for lurasidone- treated pediatric patients 10 to 17 years with bipolar depression for the SAS, BAS and AIMS was comparable to placebo-treated patients. The percentage of patients who shifted from normal to abnormal was greater in lurasidone -treated patients and placebo for the BAS (lurasidone, 4.6%; placebo, 2.4%), the SAS (lurasidone, 0.6%; placebo, 0%) and was the same for the AIMS (lurasidone, 0%; placebo, 0%). &nbsp;</p><p>&nbsp;</p><p><em><u>Dystonia </u></em></p><p><em>Class Effect: </em>Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first-generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.</p><p>&nbsp;</p><p>&middot;&nbsp;<strong><em>Schizophrenia </em></strong></p><p><em>Adults </em></p><p>In the short-term, placebo-controlled schizophrenia clinical studies, dystonia occurred in 4.2% of lurasidone-treated subjects (0.0% lurasidone 20 mg, 3.5% lurasidone 40 mg, 4.5% lurasidone 80 mg, 6.5% lurasidone 120 mg and 2.5% lurasidone 160 mg) compared to 0.8% of subjects receiving placebo. Seven subjects (0.5%, 7/1508) discontinued clinical trials due to dystonic events &ndash; four were receiving lurasidone 80 mg/day and three were receiving lurasidone 120 mg/day.</p><p>&nbsp;</p><p><em>Adolescents </em></p><p>In the short-term, placebo-controlled, adolescent schizophrenia study, dystonia occurred in 1% of lurasidone -treated patients (1% lurasidone 40 mg and 1% lurasidone 80 mg) compared to 0% of patients receiving placebo. No patients discontinued the clinical study due to dystonic events.</p><p>&nbsp;</p><p>&middot;&nbsp;<strong><em>Bipolar Depression </em></strong></p><p><u>Adults </u></p><p><em>Monotherapy </em></p><p>In the adult short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, dystonia occurred in 0.9% of lurasidone -treated subjects (0.0% and 1.8% for lurasidone 20 to 60 mg/day and lurasidone 80 to 120 mg/day, respectively) compared to 0.0% of subjects receiving placebo. No subject discontinued the clinical study due to dystonic events.</p><p>&nbsp;</p><p><em>Adjunctive Therapy with Lithium or Valproate </em></p><p>In the adult short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression studies, dystonia occurred in 1.1% of lurasidone -treated subjects (20 to 120 mg) compared to 0.6% of subjects receiving placebo. No subject discontinued the clinical study due to dystonic events.</p><p>&nbsp;</p><p><u>Pediatric Patients (10 to 17 years) </u></p><p>In the 6-week, placebo-controlled bipolar depression study in pediatric patients 10 to 17 years, dystonia occurred in 0.6% of lurasidone-treated patients compared to 1.2% of patients receiving placebo. No patients discontinued the clinical study due to dystonic events.</p><p>&nbsp;</p><p><em><u>Other Adverse Reactions Observed During the Premarketing Evaluation of lurasidone </u></em></p><p>Following is a list of adverse reactions reported by adult patients treated with lurasidone at multiple doses of &ge; 20 mg once daily within the premarketing database of 2905 patients with schizophrenia. The reactions listed are those that could be of clinical importance, as well as reactions that are plausibly drug-related on pharmacologic or other grounds. Reactions listed in Table 19 or those that appear elsewhere in the lurasidone label are not included.</p><p>Reactions are further categorized by organ class and listed in order of decreasing frequency according to the following definitions: those occurring in at least 1/100 patients (frequent) (only those not already listed in the tabulated results from placebo-controlled studies appear in this listing); those occurring in 1/100 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 patients (rare).</p><p>&nbsp;</p><p><em>Blood and Lymphatic System Disorders:</em> <strong>Infrequent: </strong>anemia</p><p><em>Cardiac Disorders:</em> <strong>Frequent: </strong>tachycardia; <strong>Infrequent: </strong>AV block 1st degree, angina pectoris, bradycardia</p><p><em>Ear and Labyrinth Disorders:</em> <strong>Infrequent: </strong>vertigo</p><p><em>Eye Disorders:</em> <strong>Frequent: </strong>blurred vision</p><p><em>Gastrointestinal Disorders</em>: <strong>Frequent: </strong>abdominal pain, diarrhea; <strong>Infrequent: </strong>gastritis</p><p><em>General Disorders and Administrative Site Conditions</em>: <strong>Rare: </strong>sudden death</p><p><em>Investigations:</em> <strong>Frequent: </strong>CPK increased</p><p><em>Metabolism and Nutritional System Disorders:</em> <strong>Frequent: </strong>decreased appetite</p><p><em>Musculoskeletal and Connective Tissue Disorders</em>: <strong>Rare: </strong>rhabdomyolysis</p><p><em>Nervous System Disorders:</em> <strong>Infrequent: </strong>cerebrovascular accident, dysarthria</p><p><em>Psychiatric Disorders:</em> <strong>Infrequent: </strong>abnormal dreams, panic attack, sleep disorder</p><p><em>Renal and Urinary Disorders:</em> <strong>Infrequent: </strong>dysuria; <strong>Rare: </strong>renal failure</p><p><em>Reproductive System and Breast Disorders</em>: <strong>Infrequent: </strong>amenorrhea, dysmenorrhea; <strong>Rare: </strong>breast enlargement, breast pain, galactorrhea, erectile dysfunction</p><p><em>Skin and Subcutaneous Tissue Disorders:</em> <strong>Frequent: </strong>rash, pruritus; <strong>Rare: </strong>angioedema</p><p><em>Vascular Disorders</em>: <strong>Frequent: </strong>hypertension</p><p>&nbsp;</p><p><em><u>Clinical Laboratory Changes </u></em></p><p>&middot;&nbsp;<em>Schizophrenia </em></p><p><u>Adults </u></p><p><em>Serum Creatinine</em>: In short-term, placebo-controlled trials, the mean change from Baseline in serum creatinine was +0.05 mg/dL for lurasidone-treated patients compared to +0.02 mg/dL for placebo-treated patients. A creatinine shift from normal to high occurred in 3.0% (43/1453) of lurasidone-treated patients and 1.6% (11/681) on placebo. The threshold for high creatinine value varied from &gt; 0.79 to &gt; 1.3 mg/dL based on the centralized laboratory definition for each study (Table 29).</p><p>&nbsp;</p><p><strong>Table 29: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in Adult Schizophrenia Studies</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Laboratory Parameter</strong></p></td><td><p><strong>Placebo (N=708)</strong></p></td><td><p><strong>Lurasidone</strong></p><p><strong>20 mg/day (N=71)</strong></p></td><td><p><strong>Lurasidone</strong></p><p><strong>40 mg/day (N=487)</strong></p></td><td><p><strong>Lurasidone</strong></p><p><strong>80 mg/day (N=538)</strong></p></td><td><p><strong>Lurasidone</strong></p><p><strong>120 mg/day (N=291)</strong></p></td><td><p><strong>Lurasidone</strong></p><p><strong>A 160 mg/day (N=121)</strong></p></td></tr><tr><td><p><strong>Serum Creatinine Elevated</strong></p></td><td><p>2%</p></td><td><p>1%</p></td><td><p>2%</p></td><td><p>2%</p></td><td><p>5%</p></td><td><p>7%</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Adolescents </u></p><p><em>Serum Creatinine</em>: In the short-term, placebo-controlled, adolescent schizophrenia study, the mean change from Baseline in serum creatinine was -0.009 mg/dL for lurasidone-treated patients compared to +0.017 mg/dL for placebo-treated patients. A creatinine shift from normal to high (based on the centralized laboratory definition) occurred in 7.2% (14/194) of lurasidone -treated patients and 2.9% (3/103) on placebo (Table 30).</p><p>&nbsp;</p><p><strong>Table 30: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in the Adolescent Schizophrenia Study</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Laboratory Parameter</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>&nbsp;(N=103)</strong></p></td><td><p><strong>Lurasidone</strong></p><p><strong>40 mg/day </strong></p><p><strong>(N=97)</strong></p></td><td><p><strong>Lurasidone</strong></p><p><strong>80 mg/day</strong></p><p><strong>&nbsp;(N=97)</strong></p></td></tr><tr><td><p><strong>Serum Creatinine Elevated</strong></p></td><td><p>2.9%</p></td><td><p>7.2%</p></td><td><p>7.2%</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p>&middot;&nbsp;<strong><em>Bipolar Depression </em></strong></p><p><em>Adults</em></p><p><u>Monotherapy </u></p><p><em>Serum Creatinine</em>: In the adult short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, the mean change from Baseline in serum creatinine was +0.01 mg/dL for lurasidone-treated patients compared to -0.02 mg/dL for placebo-treated patients. A creatinine shift from normal to high occurred in 2.8% (9/322) of lurasidone-treated patients and 0.6% (1/162) on placebo (Table 31).</p><p>&nbsp;</p><p><strong>Table 31: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in the Adult Monotherapy Bipolar Depression Study</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Laboratory Parameter</strong></p></td><td><p><strong>Placebo </strong></p><p><strong>(N=168)</strong></p></td><td><p><strong>Lurasidone</strong></p><p><strong>20 to 60 mg/day</strong></p><p><strong>(N=164)</strong></p><p><strong>&nbsp;</strong></p></td><td><p><strong>Lurasidone</strong></p><p><strong>80 to 120 mg/day</strong></p><p><strong>(N=167)</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td><p><strong>Serum Creatinine Elevated</strong></p></td><td><p>&lt;1%</p></td><td><p>2%</p></td><td><p>4%</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><u>Adjunctive Therapy with Lithium or Valproate </u></p><p><em>Serum Creatinine</em>: In adult short-term, placebo-controlled premarketing adjunctive-studies</p><p>for bipolar depression, the mean change from Baseline in serum creatinine was +0.04 mg/dL for lurasidone-treated patients compared to -0.01 mg/dL for placebo-treated patients. A creatinine shift from normal to high occurred in 4.3% (15/360) of lurasidone-treated patients and 1.6% (5/334) on placebo (Table 32).</p><p>&nbsp;</p><p><strong>Table 32: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in the Adult Adjunctive Therapy Bipolar Depression Studies</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Laboratory Parameter</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>&nbsp;(N=334)</strong></p></td><td><p><strong>Lurasidone</strong></p><p><strong>20 to 120 mg/day</strong></p><p><strong>(N=360)</strong></p></td></tr><tr><td><p><strong>Serum Creatinine Elevated</strong></p></td><td><p>2%</p></td><td><p>4%</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><em>Pediatric Patients (10 to 17 years) </em></p><p><em>Serum Creatinine</em>: In the 6-week, placebo-controlled bipolar depression study in pediatric patients 10 to 17 years, the mean change from Baseline in serum creatinine was +0.021 mg/dL for lurasidone-treated patients compared to +0.009 mg/dL for placebo-treated patients. A creatinine shift from normal to high (based on the centralized laboratory definition) occurred in 6.7% (11/163) of lurasidone -treated patients and 4.5% (7/155) on placebo (Table 33).</p><p>&nbsp;</p><p><strong>Table 33: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in the Bipolar Depression Study in Pediatric Patients (10 to 17 years)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Laboratory Parameter</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>&nbsp;(N=155)</strong></p></td><td><p><strong>Lurasidone</strong></p><p><strong>20 to 80 mg/day</strong></p><p><strong>(N=163)</strong></p></td></tr><tr><td><p><strong>Serum Creatinine Elevated</strong></p></td><td><p>4.5%</p></td><td><p>6.7%</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong><u>Postmarketing Experience </u></strong></p><p>The following adverse reactions have been identified during postapproval use of lurasidone. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p>Hypersensitivity Reactions: Urticaria, throat swelling, tongue swelling, dyspnea and rash.</p><p>Metabolism and Nutrition Disorders: Hyponatremia</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance Center (NPC)</p><p>Fax: + (966-11) 2057662</p><p>Call NPC at: + (966-11) 2038222, Exts: 2317-2356-2340.</p><p>SFDA Call Center: 19999</p><p>e-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC States</p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Human Experience </strong></p><p>In premarketing clinical studies, accidental or intentional overdosage of lurasidone was identified in one patient who ingested an estimated 560 mg of lurasidone. This patient recovered without sequelae. This patient resumed lurasidone treatment for an additional two months.</p><p><strong>&nbsp;</strong></p><p><strong>Management of Overdosage </strong></p><p>No specific antidotes for lurasidone are known. In managing overdose, provide supportive care, including close medical supervision and monitoring, and consider the possibility of multiple drug involvement.</p><p>Cardiovascular monitoring should commence immediately, including continuous electrocardiographic monitoring for possible arrhythmias. If antiarrhythmic therapy is administered, disopyramide, procainamide, and quinidine carry a theoretical hazard of additive QT-prolonging effects when administered in patients with an acute overdose of lurasidone. Similarly, the alpha-blocking properties of bretylium might be additive to those of lurasidone, resulting in problematic hypotension.</p><p>Hypotension and circulatory collapse should be treated with appropriate measures. Epinephrine and dopamine should not be used, or other sympathomimetics with beta-agonist activity, since beta stimulation may worsen hypotension in the setting of lurasidone-induced alpha blockade. In case of severe extrapyramidal symptoms, anticholinergic medication should be administered.</p><p>Gastric lavage (after intubation if patient is unconscious) and administration of activated charcoal together with a laxative should be considered.</p><p>The possibility of obtundation, seizures, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Description</strong></p><p>Laroza is an atypical antipsychotic belonging to the chemical class of benzisothiazol derivatives.</p><p>Its chemical name is (3a<em>R</em>,4<em>S</em>,7<em>R</em>,7a<em>S</em>)-2-{(1<em>R</em>,2<em>R</em>)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl] cyclohexylmethyl}hexahydro-4,7-methano-2<em>H</em>-isoindole-1,3-dione hydrochloride. Its molecular formula is C28H36N4O2S&middot;HCl and its molecular weight is 529.14.</p><p>The chemical structure is:</p><p><img alt="" width="596" height="279" src="data:image/png;base64,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" /></p><p>Lurasidone hydrochloride is a white to off-white powder. It is very slightly soluble in water, practically insoluble or insoluble in 0.1 N HCl, slightly soluble in ethanol, sparingly soluble in methanol, practically insoluble or insoluble in toluene and very slightly soluble in acetone.</p><p>&nbsp;</p><p><strong>Mechanism of Action </strong></p><p>The mechanism of action of lurasidone in the treatment of schizophrenia and bipolar depression is unknown. However, its efficacy in schizophrenia and bipolar depression could be mediated through a combination of central dopamine D2 and serotonin Type 2 (5HT2A) receptor antagonism.</p><p>&nbsp;</p><p><strong>Pharmacodynamics </strong></p><p>Lurasidone is an antagonist with high affinity binding at the dopamine D2 receptors (Ki of 1 nM) and the serotonin 5-HT2A (Ki of 0.5 nM) and 5-HT7 (Ki of 0.5 nM) receptors. It also binds with moderate affinity to the human &alpha;2C adrenergic receptors (Ki of 11 nM), is a partial agonist at serotonin 5-HT1A (Ki of 6.4 nM) receptors, and is an antagonist at the &alpha;2A adrenergic receptors (Ki of 41 nM). Lurasidone exhibits little or no affinity for histamine H1 and muscarinic M1 receptors (IC50 &gt; 1,000 nM).</p><p>&nbsp;</p><p><em><u>ECG Changes </u></em></p><p>The effects of lurasdidone on the QTc interval were evaluated in a randomized, double-blind, multiple-dose, parallel-dedicated thorough QT study in 43 patients with schizophrenia or schizoaffective disorder, who were treated with lurasdidone doses of 120 mg daily, 600 mg daily and completed the study. The maximum mean (upper 1-sided, 95% CI) increase in baseline-adjusted QTc intervals based on individual correction method (QTcI) was 7.5 (11.7) ms and 4.6 (9.5) ms, for the 120 mg and 600 mg dose groups respectively, observed at 2 to 4 hours after dosing. In this study, there was no apparent dose (exposure)-response relationship.</p><p>In short-term, placebo-controlled studies in schizophrenia and bipolar depression, no post-baseline QT prolongations exceeding 500 msec were reported in patients treated with lurasdidone or placebo.</p><p>&nbsp;</p><p><strong>Clinical studies </strong></p><p>&middot;&nbsp;<em>Schizophrenia </em></p><p><u>Adults </u></p><p>The efficacy of lurasidone for the treatment of schizophrenia was established in five short-term (6-week), placebo-controlled studies in adult patients (mean age of 38.4 years, range 18-72) who met DSM-IV criteria for schizophrenia. An active-control arm (olanzapine or quetiapine extended-release) was included in two studies to assess assay sensitivity.</p><p>&nbsp;</p><p>Several instruments were used for assessing psychiatric signs and symptoms in these studies:</p><p>1.&nbsp;Positive and Negative Syndrome Scale (PANSS), is a multi-item inventory of general psychopathology used to evaluate the effects of drug treatment in schizophrenia. PANSS total scores may range from 30 to 210.</p><p>2.&nbsp;Brief Psychiatric Rating Scale derived (BPRSd), derived from the PANSS, is a multi-item inventory primarily focusing on positive symptoms of schizophrenia, whereas the PANSS includes a wider range of positive, negative and other symptoms of schizophrenia. The BPRSd consists of 18 items rated on a scale of 1 (not present) to 7 (severe). BPRSd scores may range from 18 to 126.</p><p>3.&nbsp;The Clinical Global Impression severity scale (CGI-S) is a clinician-rated scale that measures the subject&rsquo;s current illness state on a 1- to 7-point scale.</p><p>The endpoint associated with each instrument is change from baseline in the total score to the end of week 6. These changes are then compared to placebo changes for the drug and control groups.</p><p>&nbsp;</p><p>The results of the studies follow:</p><p>1.&nbsp;Study 1: In a 6-week, placebo-controlled trial (N=145) involving two fixed doses of lurasidone (40 or 120 mg/day), both doses of lurasidone at Endpoint were superior to placebo on the BPRSd total score, and the CGI-S.</p><p>2.&nbsp;Study 2: In a 6-week, placebo-controlled trial (N=180) involving a fixed dose of lurasidone (80 mg/day), lurasidone at Endpoint was superior to placebo on the BPRSd total score, and the CGI-S.</p><p>3. Study 3: In a 6-week, placebo- and active-controlled trial (N=473) involving two fixed doses of lurasidone (40 or 120 mg/day) and an active control (olanzapine), both lurasidone doses and the active control at Endpoint were superior to placebo on the PANSS total score, and the CGI-S.</p><p>4.&nbsp;Study 4: In a 6-week, placebo-controlled trial (N=489) involving three fixed doses of lurasidone (40, 80 or 120 mg/day), only the 80 mg/day dose of lurasidone at Endpoint was superior to placebo on the PANSS total score, and the CGI-S.</p><p>5.&nbsp;Study 5: In a 6-week, placebo- and active-controlled trial (N=482) involving two fixed doses of lurasidone (80 or 160 mg/day) and an active control (quetiapine extended-release), both lurasidone doses and the active control at Endpoint were superior to placebo on the PANSS total score, and the CGI-S.</p><p>Thus, the efficacy of lurasidone at doses of 40, 80, 120 and 160 mg/day has been established (Table 34).</p><p>&nbsp;</p><p><strong>Table 34: Primary Efficacy Results for Studies in Adult Patients with Schizophrenia (BPRSd or PANSS Scores)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>&nbsp;</strong></p><p><strong>Study</strong></p></td><td rowspan="2"><p><strong>&nbsp;</strong></p><p><strong>Treatment Group</strong></p></td><td colspan="3"><p><strong>Primary Efficacy Measure: BPRSd</strong></p></td></tr><tr><td><p><strong>Mean Baseline Score (SD)</strong></p></td><td><p><strong>LS Mean Change from Baseline (SE)</strong></p></td><td><p><strong>Placebo-subtracted Difference<sup>a </sup>(95% CI)</strong></p></td></tr><tr><td><p><strong>1</strong></p></td><td><p>Lurasidone (40 mg/day)*</p><p>&nbsp;</p><p>Lurasidone (120 mg/day)*</p><p>&nbsp;</p><p>Placebo</p></td><td><p>54.2 (8.8)</p><p>&nbsp;</p><p>&nbsp;</p><p>52.7 (7.6)</p><p>&nbsp;</p><p>&nbsp;</p><p>54.7 (8.1)</p></td><td><p>-9.4 (1.6)</p><p>&nbsp;</p><p>&nbsp;</p><p>-11.0 (1.6)</p><p>&nbsp;</p><p>&nbsp;</p><p>-3.8 (1.6)</p></td><td><p>-5.6 (-9.8, -1.4)</p><p>&nbsp;</p><p>&nbsp;</p><p>-6.7 (-11.0, -2.5)</p><p>&nbsp;</p><p>&nbsp;</p><p>--</p></td></tr><tr><td><p><strong>2</strong></p></td><td><p>Lurasidone (80 mg/day)*</p><p>&nbsp;</p><p>Placebo</p></td><td><p>55.1 (6.0)</p><p>&nbsp;</p><p>&nbsp;</p><p>56.1 (6.8)</p></td><td><p>-8.9 (1.3)</p><p>&nbsp;</p><p>&nbsp;</p><p>-4.2 (1.4)</p></td><td><p>-4.7 (-8.3, -1.1)</p><p>&nbsp;</p><p>&nbsp;</p><p>--</p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>&nbsp;</p></td><td colspan="3"><p><strong>Primary Efficacy Measure: PANSS</strong></p></td></tr><tr><td><p><strong>3</strong></p></td><td><p>Lurasidone (40 mg/day)*</p><p>&nbsp;</p><p>Lurasidone (120 mg/day)*</p><p>&nbsp;</p><p>Olanzapine (15 mg/day)*<sup>b</sup></p><p>&nbsp;</p><p>Placebo</p></td><td><p>96.6 (10.7)</p><p>&nbsp;</p><p>&nbsp;</p><p>97.9 (11.3)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;96.3 (12.2)</p><p>&nbsp;</p><p>&nbsp;</p><p>95.8 (10.8)</p></td><td><p>-25.7 (2.0)</p><p>&nbsp;</p><p>&nbsp;</p><p>-23.6 (2.1)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;-28.7 (1.9)</p><p>&nbsp;</p><p>&nbsp;</p><p>-16.0 (2.1)</p></td><td><p>-9.7 (-15.3, -4.1)</p><p>&nbsp;</p><p>&nbsp;</p><p>-7.5 (-13.4, -1.7)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp; -12.6 (-18.2, -7.9)</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; --</p></td></tr><tr><td><p><strong>4</strong></p></td><td><p>Lurasidone (40 mg/day)</p><p>&nbsp;</p><p>Lurasidone (80 mg/day) *</p><p>&nbsp;</p><p>Lurasidone (120 mg/day)</p><p>&nbsp;</p><p>Placebo</p></td><td><p>96.5 (11.5)</p><p>&nbsp;</p><p>&nbsp;</p><p>96.0 (10.8)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;96.0 (9.7)</p><p>&nbsp;</p><p>&nbsp;</p><p>96.8 (11.1)</p></td><td><p>-19.2 (1.7)</p><p>&nbsp;</p><p>&nbsp;</p><p>-23.4 (1.8)</p><p>&nbsp;</p><p>&nbsp;</p><p>-20.5 (1.8)</p><p>&nbsp;</p><p>&nbsp;</p><p>-17.0 (1.8)</p></td><td><p>-2.1 (-7.0, 2.8)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp; -6.4 (-11.3, -1.5)</p><p>&nbsp;</p><p>-3.5 (-8.4, 1.4)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp; --</p></td></tr><tr><td><p><strong>5</strong></p></td><td><p>Lurasidone (80 mg/day)*</p><p>&nbsp;</p><p>Lurasidone (160 mg/day)*</p><p>&nbsp;</p><p>Quetiapine Extended-release (600 mg/day)*<sup>b </sup></p><p>&nbsp;</p><p>Placebo</p></td><td><p>97.7 (9.7)</p><p>&nbsp;</p><p>&nbsp;</p><p>97.5 (11.8)</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p>97.7 (10.2)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>96.6 (10.2)</p></td><td><p>-22.2 (1.8)</p><p>&nbsp;</p><p>&nbsp;</p><p>-26.5 (1.8)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>-27.8 (1.8)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;-10.3 (1.8)</p></td><td><p>-11.9 (-16.9, -6.9)</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp; -16.2 (-21.2, -11.2)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp; -17.5 (-22.5, -12.4)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p>--</p></td></tr></tbody></table><p>SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: confidence interval, unadjusted for multiple comparisons.</p><p>&nbsp;<sup>a </sup>Difference (drug minus placebo) in least-squares mean change from baseline.</p><p>&nbsp;<sup>b </sup>Included for assay sensitivity.</p><p>* Doses statistically significantly superior to placebo.</p><p>&nbsp;</p><p>Examination of population subgroups based on age (there were few patients over 65), gender and race did not reveal any clear evidence of differential responsiveness.</p><p>&nbsp;</p><p><u>Adolescents (13-17 years) </u></p><p>The efficacy of lurasidone, was established in a 6-week, multicenter, randomized, double-blind, placebo-controlled study of adolescents (13 to 17 years) who met DSM-IV-TR criteria for schizophrenia (N=326). Patients were randomized to one of two fixed-doses of lurasidone (40 or 80 mg/day) or placebo.</p><p>The primary rating instrument used to assess psychiatric signs and symptoms was the PANSS. The key secondary instrument was the CGI-S.</p><p>For both dose groups, lurasidone was superior to placebo in reduction of PANSS and CGI-S scores at Week 6. On average, the 80 mg/day dose did not provide additional benefit compared to the 40 mg/day dose.</p><p>&nbsp;</p><p>The primary efficacy results are provided in Table 35.</p><p><strong>Table 35: Primary Efficacy Results (PANSS Total Score) for the Adolescent Schizophrenia Study</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Treatment Group</strong></p></td><td colspan="3"><p><strong>Primary Efficacy Measure: PANSS</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>Mean Baseline Score (SD)</strong></p></td><td><p><strong>LS Mean Change from Baseline (SE)</strong></p></td><td><p><strong>Placebo-subtracted Difference (95% CI)</strong></p></td></tr><tr><td><p>Lurasidone (40 mg/day)*&nbsp;</p></td><td><p>94.5 (10.97)</p></td><td><p>-18.6 (1.59)</p></td><td><p>-8.0 (-12.4, -3.7)</p></td></tr><tr><td><p>Lurasidone (80 mg/day)*&nbsp;</p></td><td><p>94.0 (11.12)</p></td><td><p>-18.3 (1.60)</p></td><td><p>-7.7 (-12.1, -3.4)</p></td></tr><tr><td><p>Placebo</p></td><td><p>92.8 (11.08)</p></td><td><p>-10.5 (1.59)</p></td><td><p>--</p></td></tr></tbody></table><p>SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: confidence interval, unadjusted for multiple comparisons.</p><p><sup>a </sup>Difference (drug minus placebo) in least-squares mean change from baseline.</p><p>* Doses statistically significantly superior to placebo.</p><p>&nbsp;</p><p>&middot;&nbsp;<em>Depressive Episodes Associated with Bipolar I Disorder </em></p><p><strong><em>Adults </em></strong></p><p><u>Monotherapy </u></p><p>The efficacy of lurasidone, as monotherapy, was established in a 6-week, multicenter, randomized, double-blind, placebo-controlled study of adult patients (mean age of 41.5 years, range 18 to 74) who met DSM-IV-TR criteria for major depressive episodes associated with bipolar I disorder, with or without rapid cycling, and without psychotic features (N=485). Patients were randomized to one of two flexible-dose ranges of lurasidone (20 to 60 mg/day, or 80 to 120 mg/day) or placebo.</p><p>The primary rating instrument used to assess depressive symptoms in this study was the Montgomery-Asberg Depression Rating Scale (MADRS), a 10-item clinician-rated scale with total scores ranging from 0 (no depressive features) to 60 (maximum score). The primary endpoint was the change from baseline in MADRS score at Week 6. The key secondary instrument was the Clinical Global Impression-Bipolar-Severity of Illness scale (CGI-BP-S), a clinician-rated scale that measures the subject&rsquo;s current illness state on a 7-point scale, where a higher score is associated with greater illness severity.</p><p>For both dose groups, lurasidone was superior to placebo in reduction of MADRS and CGI-BP-S scores at Week 6. The primary efficacy results are provided in Table 36. The high dose range (80 to 120 mg per day) did not provide additional efficacy on average, compared to the low dose range (20 to 60 mg per day).</p><p>&nbsp;</p><p><u>Adjunctive Therapy with Lithium or Valproate </u></p><p>The efficacy of lurasidone, as an adjunctive therapy with lithium or valproate, was established in a 6-week, multicenter, randomized, double-blind, placebo-controlled study of adult patients (mean age of 41.7 years, range 18 to 72) who met DSM-IV-TR criteria for major depressive episodes associated with bipolar I disorder, with or without rapid cycling, and without psychotic features (N=340). Patients who remained symptomatic after treatment with lithium or valproate were randomized to flexibly dosed lurasidone 20 to 120 mg/day or placebo.</p><p>The primary rating instrument used to assess depressive symptoms in this study was the MADRS. The primary endpoint was the change from baseline in MADRS score at Week 6. The key secondary instrument was the CGI-BP-S scale.</p><p>Lurasidone was superior to placebo in reduction of MADRS and CGI-BP-S scores at Week 6, as an adjunctive therapy with lithium or valproate (Table 36).</p><p>&nbsp;</p><p><strong>Table 36: Primary Efficacy Results for Adult Studies in Depressive Episodes Associated with Bipolar I Disorder (MADRS Scores)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>Study</strong></p></td><td rowspan="2"><p><strong>&nbsp;</strong></p><p><strong>Treatment Group</strong></p></td><td colspan="3"><p><strong>Primary Efficacy Measure: MADRS</strong></p></td></tr><tr><td><p><strong>Mean Baseline Score (SD)</strong></p></td><td><p><strong>LS Mean Change from Baseline (SE)</strong></p></td><td><p><strong>Placebo-subtracted Difference<sup>a&nbsp; </sup>(95% CI)</strong></p></td></tr><tr><td><p>Monotherapy study</p></td><td><p>Lurasidone (20-60mg/day)*</p><p>&nbsp;</p><p>Lurasidone (80-120 mg/day)*</p><p>&nbsp;</p><p>Placebo</p></td><td><p>&nbsp;30.3 (5.0)</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30.6 (4.9)</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30.5 (5.0)</p></td><td><p>-15.4 (0.8)</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -15.4 (0.8)</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -10.7 (0.8)</p></td><td><p>-4.6 (-6.9, -2.3)</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -4.6 (-6.9, -2.3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; --</p></td></tr><tr><td><p>Adjunctive Therapy study</p></td><td><p>Lurasidone (20-120 mg/day)* + lithium or valproate</p><p>&nbsp;</p><p>Placebo + lithium or valproate</p></td><td><p>30.6 (5.3)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>30.8 (4.8)</p></td><td><p>-8.9 (1.3)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>-4.2 (1.4)</p></td><td><p>-3.6 (-6.0, -1.1)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>--</p></td></tr></tbody></table><p>SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: confidence interval, unadjusted for multiple comparisons.</p><p>&nbsp;<sup>a </sup>Difference (drug minus placebo) in least-squares mean change from baseline. * Treatment group statistically significantly superior to placebo.</p><p>&nbsp;</p><p><strong><em>Pediatric Patients (10 to 17 years) </em></strong></p><p>The efficacy of lurasidone was established in a 6-week, multicenter, randomized, double-blind, placebo-controlled study of pediatric patients (10 to 17 years) who met DSM-5 criteria for a major depressive episode associated with bipolar I disorder, with or without rapid cycling, and without psychotic features (N=343). Patients were randomized to flexibly dosed lurasidone 20 to 80 mg/day or placebo. At the end of the clinical study, most patients (67%) received 20 mg/day or 40 mg/day.</p><p>The primary rating scale used to assess depressive symptoms in this study was the Children&rsquo;s Depression Rating Scale, Revised (CDRS-R) total score. The CDRS-R is a 17-item clinician-rated scale with total scores ranging from 17 to 113. The primary endpoint was the change from baseline in CDRS-R score at Week 6. The key secondary endpoint was the change from baseline in CGI-BP-S depression score.</p><p>Lurasidone was superior to placebo in reduction of CDRS-R total score and CGI-BP-S depression score at Week 6. The primary efficacy results are provided in Table 37.</p><p>&nbsp;</p><p><strong>Table 37 Primary Efficacy Results for the Study in Depressive Episodes Associated with Bipolar I Disorder (CDRS-R Total Score) in Pediatric Patients (10 to 17 years)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Treatment Group</strong></p></td><td colspan="3"><p><strong>Primary Efficacy Measure: CDRS-R</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>Mean Baseline Score (SD)</strong></p></td><td><p><strong>LS Mean Change from Baseline (SE)</strong></p></td><td><p><strong>Placebo-subtracted Difference (95% CI)</strong></p></td></tr><tr><td><p>Lurasidone (20 to 80 mg/day)*&nbsp;</p></td><td><p>59.2 (8.24)</p></td><td><p>-21.0 (1.06)</p></td><td><p>-5.7 (-8.4,-3.0)</p></td></tr><tr><td><p>Placebo</p></td><td><p>58.6 (8.26)</p></td><td><p>-15.3 (1.08)</p></td><td><p>--</p></td></tr></tbody></table><p>SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: confidence interval, unadjusted for multiple comparisons.</p><p>&nbsp;<sup>a </sup>Difference (drug minus placebo) in least-squares mean change from baseline.</p><p>&nbsp;* Treatment group statistically significantly superior to placebo.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Adults </u></p><p>The activity of lurasidone is primarily due to the parent drug. The pharmacokinetics of lurasidone is dose-proportional within a total daily dose range of 20 mg to 160 mg. Steady-state concentrations of lurasidone are reached within 7 days of starting lurasidone.</p><p>Following administration of 40 mg of lurasidone, the mean (%CV) elimination half-life was 18 (7) hours.</p><p>&nbsp;</p><p><em>Absorption and Distribution: </em>lurasidone is absorbed and reaches peak serum concentrations in approximately 1-3 hours. It is estimated that 9-19% of an administered dose is absorbed. Following administration of 40 mg of lurasidone, the mean (%CV) apparent volume of distribution was 6173 (17.2) L. lurasidone is highly bound (~99%) to serum proteins.</p><p>In a food effect study, lurasidone mean C<sub><sup>max</sup></sub> and AUC were about 3-times and 2-times, respectively, when administered with food compared to the levels observed under fasting conditions. Lurasidone exposure was not affected as meal size was increased from 350 to 1000 calories and was independent of meal fat content.</p><p>In clinical studies, establishing the safety and efficacy of lurasidone, patients were instructed to take their daily dose with food.</p><p>&nbsp;</p><p><em>Metabolism and Elimination: </em>Lurasidone is metabolized mainly via CYP3A4. The major biotransformation pathways are oxidative <em>N</em>-dealkylation, hydroxylation of norbornane ring, and <em>S</em>-oxidation. Lurasidone is metabolized into two active metabolites (ID-14283 and ID-14326) and two major non-active metabolites (ID-20219 and ID-20220). Based on <em>in vitro </em>studies, lurasidone is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP4A11, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP2E1 enzymes. Because lurasidone is not a substrate for CYP1A2, smoking is not expected to have an effect on the pharmacokinetics of lurasidone.</p><p>&nbsp;</p><p><em>Transporter proteins: In vitro </em>studies suggest lurasidone is not a substrate of OATP1B1 or OATP1B3, however, is probably a substrate of P-gp and BCRP. <em>In vitro </em>studies indicate that lurasidone is not expected to inhibit transporters OATP1B1, OATP1B3, OCT1, OCT2, OAT1, OAT3, MATE1, MATE2-K and BSEP at clinically relevant concentrations. Lurasidone is not a clinically significant inhibitor of P-gp. However, it may inhibit BCRP.</p><p>Total excretion of radioactivity in urine and feces combined was approximately 89%, with about 80% recovered in feces and 9% recovered in urine, after a single dose of [<sup>14</sup>C]-labeled lurasidone.</p><p>Following administration of 40 mg of lurasidone, the mean (%CV) apparent clearance was 3902 (18.0) mL/min.</p><p>&nbsp;</p><p><u>Drug Interaction Studies </u></p><p>Effects of other drugs on the exposure of lurasidone are summarized in Figure 1. A population PK analyses concluded that coadministration of lithium 300-2400 mg/day or valproate 300-2000 mg/day with lurasidone for up to 6 weeks has minimal effect on lurasidone exposure.</p><p>And the effects of lurasidone on the exposures of other drugs are summarized in Figure 2. A population PK analyses concluded that coadministration of lurasidone has minimal effect on lithium and valproate exposure when it is coadministered with lithium 300-2400 mg/day or valproate 300-2000 mg/day.</p><p>&nbsp;</p><p><strong>Figure 1: Impact of Other Drugs on lurasidone Pharmacokinetics </strong></p><p><img alt="" width="763" height="542" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Figure 2: Impact of lurasidone on Other Drugs</strong></p><p><img alt="" width="925" height="515" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p><u>Studies in Specific Populations </u></p><p>The effect of intrinsic patient factors on the pharmacokinetics of lurasidone is presented in Figure 3.</p><p>&nbsp;</p><p><u>Pediatric Patients </u></p><p>Lurasidone exposure (i.e., steady-state C<sub>max</sub> and AUC) in children and adolescent patients (10 to 17 years of age) was generally similar to that in adults across the dose range from 40 to 160 mg, without adjusting for body weight.</p><p>&nbsp;</p><p><strong>Figure 3: Impact of Other Patient Factors on Lurasidone Pharmacokinetics</strong></p><p><strong><img alt="" width="576" height="523" src="data:image/png;base64,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" /></strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Carcinogenesis, Mutagenesis, Impairment of Fertility </strong></p><p><em>Carcinogenesis: </em>Lurasidone increased incidences of malignant mammary gland tumors and pituitary gland adenomas in female mice orally dosed with 30, 100, 300, or 650 mg/kg/day. The lowest dose produced plasma levels (AUC) approximately equal to those in humans receiving the MRHD of 160 mg/day. No increases in tumors were seen in male mice up to the highest dose tested, which produced plasma levels (AUC) 14 times those in humans receiving the MRHD.</p><p>Lurasidone increased the incidence of mammary gland carcinomas in female rats orally dosed at 12 and 36 mg/kg/day: the lowest dose; 3 mg/kg/day is the no-effect dose which produced plasma levels (AUC) 0.4 times those in humans receiving the MRHD. No increases in tumors were seen in male rats up to the highest dose tested, which produced plasma levels (AUC) 6 times those in humans receiving the MRHD.</p><p>Proliferative and/or neoplastic changes in the mammary and pituitary glands of rodents have been observed following chronic administration of antipsychotic drugs and are considered to be prolactin-mediated.</p><p><em>&nbsp;</em></p><p><em>Mutagenesis: </em>Lurasidone did not cause mutation or chromosomal aberration when tested <em>in vitro </em>and <em>in vivo test battery</em>. Lurasidone was negative in the Ames gene mutation test, the Chinese Hamster Lung (CHL) cells, and in the <em>in vivo </em>mouse bone marrow micronucleus test up to 2000 mg/kg which is 61 times the MRHD of 160 mg/day based on mg/m<sup>2 </sup>body surface area.</p><p>&nbsp;</p><p><em>Impairment of Fertility: </em>Estrus cycle irregularities were seen in rats orally administered lurasidone at 1.5, 15 and 150 mg/kg/day for 15 consecutive days prior to mating, during the mating period, and through gestation day 7. No effect was seen at the lowest dose of 0.1 mg/kg which is approximately 0.006 times the MRHD of 160 mg/day based on mg/m<sup>2</sup>. Fertility was reduced only at the highest dose, which was reversible after a 14 day drug-free period. The no-effect dose for reduced fertility was approximately equal to the MRHD based on mg/m<sup>2</sup>.</p><p>Lurasidone had no effect on fertility in male rats treated orally for 64 consecutive days prior to mating and during the mating period at doses up to 9 times the MRHD based on mg/m<sup>2</sup>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">-&nbsp;&nbsp;Lactose monohydrate</p><p style="text-align:justify">-&nbsp;&nbsp;Mannitol</p><p style="text-align:justify">-&nbsp; Pregelatinized starch</p><p style="text-align:justify">-&nbsp;&nbsp;Croscarmellose sodium</p><p style="text-align:justify">-&nbsp; Povidone</p><p style="text-align:justify">-&nbsp; &nbsp;Citric acid anhydrous</p><p style="text-align:justify">-&nbsp; Magnesium stearate</p><p style="text-align:justify">-&nbsp; &nbsp;Opadry white 03B28796:</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; Hypromellose</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; Titanium dioxide</p><p style="text-align:justify">&middot;&nbsp;&nbsp;&nbsp; Polyethylene glycol.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30ᵒC.</p><p>Store in the original package.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminum-aluminum blisters.</p><p>Pack size: 30 Film-coated Tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. BOX 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 4980170            
Fax: + (966-11) 4980187
e-mail: medical@jpi.com.sa

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                25 May 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>